

UNITED STATES DISTRICT COURT  
FOR THE  
DISTRICT OF MASSACHUSETTS

---

JOHN HANCOCK LIFE INSURANCE )  
COMPANY, JOHN HANCOCK )  
VARIABLE LIFE INSURANCE )  
COMPANY, and MANULIFE )  
INSURANCE COMPANY (f/k/a )  
INVESTORS PARTNER INSURANCE )  
COMPANY, ) CIVIL ACTION NO. 05-11150-DPW  
Plaintiffs, )  
v. )  
ABBOTT LABORATORIES, )  
Defendant. )  
\_\_\_\_\_  
)

**AFFIDAVIT OF KENNETH STILES**

I, Kenneth Stiles, do hereby declare and say:

1. My name is Kenneth Stiles. I am over 18 years of age and suffer from no condition or disability that would impair my ability to give sworn testimony. This affidavit is based upon my own personal knowledge.

**Educational and Professional Background**

2. I am currently employed by Abbott Laboratories (“Abbott”) as Assistant Controller for Global Pharmaceutical Research and Development (“GPRD”) Financial Business Solutions. I was appointed to that position approximately two years ago. In my current position, I am responsible for developing improvements to GPRD’s financial systems applications (*i.e.*, the computer software that is used for financial

management) and financial processes (*i.e.*, processes for approval of expenditures). I serve as a bridge between users of the financial data within Abbott, such as the financial analysts who support the research and development (“R&D”) personnel, and the information technology personnel. I report to Brian Durkin, the Senior Director of Finance and Operations.

3. I received my Bachelor of Science degree in Transportation Management from Indiana University in 1978. I received my Masters in Business Administration in Finance from DePaul University in 1982. I received a Certificate of Management Accounting in 1985.

4. I joined Abbott after graduation from college in 1978. For the first two years, I held inventory accounting positions. Starting in 1980, I held a variety of positions at Abbott in which I was responsible for financial analysis, planning, and/or accounting. The positions that I held at Abbott between 1980 and 2001 included Senior Financial Analyst in Corporate Materials Management, Senior Financial Analyst for the Pharmaceuticals Products Division (“PPD”), Senior Cost Analyst for the PPD, Supervisor of Puerto Rico Financial Operations, Manager Financial Planning and Analysis for Abbott Diagnostics Division (“ADD”), Commercial Controller for ADD United States and Canada Operations, and Controller for MediSense Operations in ADD.

5. From May 2001 to 2005, I served as Assistant Division Controller in GPRD. I reported to the GPRD Controller. When I first started, Tom Lyons was the GPRD Controller. Subsequently, during my tenure in that position Kraig Moffatt was GPRD Controller. Several individuals reported to me and worked under my direction,

including Tom Woidat and Rich Pinto. As Assistant Division Controller, I was responsible for financial planning, reporting, and controls. More specifically, with respect to planning, I worked with operations personnel in R&D to develop budgets, compared actual with budgeted spending, and highlighted variances to senior management. With respect to reporting, I compiled monthly consolidated expenditure reports for management. With respect to financial controls, I was responsible, along with others in my department, for ensuring that the financial practices complied with generally accepted accounting procedures (“GAAP”), corporate policy, and applicable laws and regulations.

6. In managing R&D operations, Abbott monitors spending by “project.” If a compound has only one indication, project refers to the overall development of that particular compound. If the compound has more than one indication (*e.g.*, a tablet form and I.V. form), “project” refers to each indication.

7. During my tenure as Assistant Division Controller, Abbott recorded its actual spending in the Financial Management System (“FMS”). I, along with others in my department, generated expense reports on a “functional” or “departmental” level from this system. The functional reports reflected spending organized by function or service area, and were the basis for submissions to Abbott Finance headquarters. These submissions were consolidated with results from other Abbott operating units and ultimately used for external reporting, such as reports filed with the Securities Exchange Commission.

8. The FMS system was not (and is not) the official system of record for project expense data. For internal management purposes, GPRD used a software

application called the Comprehensive Project Accounting System, commonly referred to as COMPASS, to record and produce reports reflecting actual expenditures by project. Under GRPD's standard procedures, manpower rates were calculated for each service area by dividing the projected total year level of spending for a service area by the number of manpower hours expected to be available that year for the service area. Overhead was allocated to each service area and built into the manpower rates. R&D personnel completed time sheets reflecting time spent on each project and those time records were entered into COMPASS. In the COMPASS system, the project expense rates were multiplied by the number of hours recorded on the project, and the resulting expense level was added to non-personnel expenditures on the project to determine the estimated actual expenditures on each project. My staff and I generated project expense reports from the COMPASS system, which reflected our reasonable estimate of actual expenditures by project. GPRD Finance routinely produced the project expense reports in the ordinary course of business in support of operating management's monitoring of actual expenditures by project.

9. Attached hereto as D's Exhibit 786 are true and correct copies of project expense reports reflecting Abbott's actual monthly and annual expenditures during 2001 on research and development of the Program Compounds that are included in the Research Funding Agreement between John Hancock and Abbott, *i.e.*, franesytransferase ("FTI"), quinolone (ABT-492), TSP Peptide (ABT-510), the MMPI program (ABT-770/ABT-518), CCM (ABT-594), endothelin (ABT-627), erectile dysfunction and dopamine (the "ED" program), Eisai (ABT-751), and ketolide (ABT-773).

10. Attached hereto as D's Exhibit FC are true and correct copies of project expense reports reflecting Abbott's actual monthly and annual expenditures in 2002 on research and development of the Program Compounds, with the exception of ABT-594.

11. Attached hereto as D's Exhibit FD is a true and correct copy of a project expense report reflecting Abbott's actual monthly and annual expenditures in 2002 on research and development of ABT-594.

12. Attached hereto as D's Exhibit FE are true and correct copies of project expense reports reflecting Abbott's actual monthly and annual expenditures in 2003 on research and development of the Program Compounds.

13. Attached hereto as D's Exhibit FF are true and correct copies of project expense reports reflecting Abbott's actual monthly and annual expenditures in 2004 on research and development of the Program Compounds.

14. Attached hereto as D's Exhibit FG are true and correct copies of project expense reports reflecting Abbott's actual monthly and annual expenditures in 2005 on research and development of the Program Compounds.

15. In the course of the Research Funding Agreement, Abbott provided Annual Research Plans ("ARPs") to Hancock, which reported, among other things, expenditures to date on the compounds. In Fall 2007, in response to what I understood to be a request by John Hancock for information regarding Abbott's actual expenditures by month during 2001, I assisted Abbott counsel with the preparation of an amended interrogatory response that would provide that information. In the course of preparing that interrogatory response, I reviewed and analyzed Abbott's project expense reports. Based on that review and analysis, I determined that the ARPs, and

Abbott's original interrogatory response that I verified on June 27, 2006, inadvertently underreported Abbott's actual expenditures during the 2001 to 2005 period on certain Program Compounds. Based on my analysis, it appears that primary omissions were expenditures incurred by Abbott between January 2001 to July 2001 on development of ABT-100 (FTI) and ABT-724 (ED/Dopamine), certain milestone payments to Wakunaga Pharmaceutical for the development of ABT-492 (quinolone), and expenditures in 2002 incurred at Abbott's Ludwigshafen facility in Germany on development of several Program Compounds.

16. It appears that the ARP and original interrogatory responses also may also have understated expenditures on ABT-773 in 2001 and 2002. A project expense report that I analyzed, which listed expenditures by timekeepers, rather than by month, reflects a higher level of expenditures by Abbott on ABT-773 in 2001 and 2002 than is reflected in the project expense reports that list expenditures by month. Based on my analysis, it appeared that the complete expenditures on the ABT-773 Japan program were not fully reflected in the project expense report listing expenditures by month. For the sake of conservatism, however, I relied on the GPRD reports listing monthly expenditures, rather than the timekeeper report, in reporting the expenditure figures for ABT-773 in Abbott's Amended Responses and Objections to Plaintiffs' Second Set of Interrogatories.

17. Attached hereto as D's Exhibit FO is a true and correct copy of Abbott's Amended Responses and Objections to Plaintiffs' Second Set of Interrogatories, which, in the amended response to Interrogatory Number 15, set forth Abbott's annual expenditures on research and development of the Program Compounds from 2001 to

2005, and which attach the project expense reports showing monthly expenditures on the Program Compounds in 2001. This concludes my testimony.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Executed on February 17, 2008 at Vernon Hills, IL.

Kenneth D. Stiles  
Kenneth Stiles

EC

20-Jan-02  
PAGE 8-11

PHATMAGEN CAN 67 JUN 2018 RSC  
S-1 BILLETTEEN FROM THE PRE-REPORT  
EN #2 (ABT-10)

CCCIV

**CONFIDENTIAL**  
**ABBT 0578016**

PROJECTS & PROJECT EXPENSE REPORT  
QUARTERLY BUDGET & ACTUAL EXPENSE REPORT

Quintiles (ABT-402)

	Jan	Feb	March	April	MONTHLY RESULTS					Oct	Nov	Dec	Total	YTD Approved LPD	YTD Actual	Projected Year-End	Actual Year-End	
					1	2	3	4	5									
Discovery	100	159	229	152	200	125	171	285	187	200	220	156	2,186	2,217	31	2,186	2,217	
Process Chemistry	483	488	481	639	339	451	378	451	337	275	156	207	37	4,283	4,929	646	4,283	4,929
Drug Safety																		
Metabolism	71	67	39	28	30	49	41	87	56	68	96	56	672	1,507	692	1,507	692	
Toxicology/Pathology	15	15	5	14	49	57	177	135	98	109	149	113	980	2,031	1,051	980	2,031	
Comparative Medicine	24	23	41	76	63	59	35	25	16	12	42	9	425	79	(346)	425	79	
Medical Affairs																		
Outcomes Res/Admin																		
Medical Services																		
Phase-I Center																		
Clinical	5	10	11	1	(15)	1	57	177	20	338	29	12	19	132	322	190	132	322
ACPRU- Direct																		
Development Operations																		
Data Management	10	21	24	24	49	41	22	43	29	32	77	44	418	971	553	418	971	
Biostatistics	9	15	15	14	9	21	13	31	35	32	22	23	239	625	386	239	625	
International Manpower																		
Grants	944	943	944	944	944	944	945	928	928	1,392	1,184	2,631	12,477	15,605	3,128	12,477	15,605	
International Directors																		
Venture Management																		
PARD	174	174	174	174	174	174	174	174	174	174	272	277	2,289	3,909	2,289	6,198	3,909	
Regulatory/RIC	117	208	272	221	353	208	253	316	169	217	(267)	114	2,161	4,087	1,926	2,161	4,087	
Research/GA																		
Strategic Scientific Operation																		
Investigational Drug QA	12	19	5	(12)	25	23	7	16	25	124	27	21	294	284	(10)	294	284	
SPD																		
License Pymt/Royalty																		
Other																		
Judgment																		
LU																		
Total Global	1,982	2,150	2,275	2,454	2,369	5,511	2,346	3,657	2,787	3,657	3,664	1,028	32,780	41,475	8,695	32,780	41,475	

COMMENTS

	FORTNIGHTLY RESULTS												YEAR-END					
	Jan	Feb	Mar	Apr	May	June	Jul	Aug	Sep	Oct	Nov	Dec	Total	Approved UED	Var	Proj Year-End	Var:	
Discovery	18	27	54	13	36	60	37	42	70	47	48	34	465	286	(197)	486	269	
Process Chemistry	110	404	393	518	484	422	378	471	656	439	88	4745	5,123	378	5,123	358		
Drug Safety	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Metabolism	57	100	52	48	114	36	46	37	17	39	41	129	716	1,644	928	716	1,644	
Toxicology/Pathology	3	2	2	2	8	3	3	5	8	7	5	20	48	263	215	48	263	
Comparative Medicine	1	3	17	-	2	5	4	11	2	5	2	2	72	175	103	72	175	
Medical Affairs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Outcomes Res/Admin	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Medical Services	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Phase-I Center	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Clinical	1	12	15	1	(26)	-	83	-	37	8	21	9	161	91	30	161	191	
ACPRU - Direct	-	-	-	-	58	-	(57)	2	-	-	-	-	3	-	(5)	3	-	
Development Operations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Data Management	2	9	8	8	10	4	3	12	21	15	18	25	135	342	207	135	342	
Biostatistics	5	9	7	6	15	9	3	7	3	2	8	7	81	338	257	81	338	
International Manpower	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Grants	110	34	-	-	-	-	17	40	-	40	40	396	-	758	5,861	5,103	758	5,861
International Directors	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Venture Management	190	154	380	212	132	211	226	259	231	243	92	2,555	2,025	(510)	2,535	2,025		
R&D	62	101	146	260	287	102	268	604	189	(257)	222	232	2,236	2,426	169	2,236	2,426	
Regulatory/RC	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Research QA	4	9	14	6	21	2	13	24	9	26	11	31	170	298	128	170	298	
Strategic Scientific Operation	-	3	2	6	2	2	1	3	2	3	2	1	27	379	352	27	379	
Investigational Drug QA	1	5	(6)	7	3	15	-	-	-	20	2	-	47	-	(47)	47	-	
SPD	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
License Pym/Royalty	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Judgement	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
U	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Total Global	574	881	1,074	-	1,103	1,168	898	-	1,056	1,596	1,407	553	1,310	1,141	12,781	19,425	6,644	

COMMENTS

CONFIDENTIAL  
ABBT0578018

MANUFACTURING & SUPPLY CHAIN  
REGULATORY AFFAIRS  
End-of-Year (AS1-627)

PAGE 8-6  
20-JULY-08  
3

	WORLWIDE RESULTS												WORLD												
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	
Discovery	17	9	29	12	20	26	11	62	73	69	72	118	518	166	(353)	518	186	(353)	518	1950	2,200	2,200	2,200	250	
Process Chemistry	26	74	102	68	140	102	206	141	91	89	85	826	1,950	2,200	250	1,950	1,950	1,950	1,950	1,950	1,950	1,950	1,950	1,950	
Drug Safety	15	14	39	59	61	50	107	149	106	119	228	95	1,042	968	(76)	1,042	968	968	968	968	968	968	968	(74)	
Metabolism	...	...	21	1	18	14	17	6	11	10	10	30	131	435	304	131	435	435	435	435	435	435	435	304	
Toxicology/Pathology	...	...	...	2	...	...	...	6	2	(6)	9	18	31	52	21	31	52	52	52	52	52	52	52	52	
Comparative Medicine	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Medical Affairs	88	206	220	221	200	179	17	40	285	17	17	16	1,506	200	(1,307)	1,506	200	200	200	(1,307)	200	200	200	(1,307)	
Outcomes Res/Admin	35	35	35	35	35	35	35	35	35	35	35	35	35	418	404	(14)	418	404	404	404	404	404	404	404	(14)
Medical Services	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Phase-I Center	11	51	1	1	15	124	232	(73)	242	29	541	86	39	1,278	1,424	146	1,278	1,424	1,424	1,424	1,424	1,424	1,424	1,424	
Clinical	...	...	43	15	15	124	232	(73)	242	29	541	86	39	1,278	1,424	146	1,278	1,424	1,424	1,424	1,424	1,424	1,424	1,424	
ACPRU - Direct	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Development Operations	54	51	138	70	110	76	88	144	153	151	268	150	1,463	2,840	1,377	1,463	2,840	2,840	2,840	2,840	2,840	2,840	2,840	1,377	
Data Management	62	117	164	115	115	127	114	166	127	179	177	88	1,577	1,335	(242)	1,577	1,335	1,335	1,335	1,335	1,335	1,335	1,335	(242)	
Biostatistics	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
International Manpower	1,964	1,964	1,965	1,965	1,965	1,965	1,965	1,964	1,964	1,964	1,964	1,964	2,174	1,732	24,409	27,344	27,344	27,344	27,344	27,344	27,344	27,344	27,344		
Grants	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
International Directors	492	400	...	549	344	549	610	672	765	688	720	276	6,005	6,021	(44)	6,005	6,021	6,021	6,021	6,021	6,021	6,021	6,021	(44)	
Venture Management	268	444	614	908	753	756	491	1,588	(325)	453	679	772	7,401	5,952	(1,449)	7,401	5,952	5,952	5,952	5,952	5,952	5,952	5,952	(1,449)	
PAOD	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Regulatory/RIC	4	21	62	57	38	23	46	15	36	19	9	41	289	645	659	14	645	659	659	659	659	659	659	14	
Strategic Scientific Operation	5	5	7	8	6	2	5	10	2	2	3	3	52	429	377	52	429	429	429	429	429	429	429	377	
Investigational Drug QA	7	7	28	(35)	44	11	26	63	300	132	164	815	370	(445)	370	370	370	370	370	370	370	370	370	(445)	
SPD	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
License Pmt/Royalty	...	...	...	...	...	...	...	7	(4)	2	1	3	(1)	3	7	309	309	309	309	309	309	309	309	302	
Other	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Judgement	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
LU	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Total Global	3,048	3,421	3,406	4,205	4,027	4,181	3,819	5,784	5,036	5,406	5,41	4,963	51,837	51,667	(170)	51,837	51,667	51,667	51,667	51,667	51,667	51,667	(170)		

COMMENIS

CONFIDENTIAL  
ABBTO578019

PAGE B-34

### Dopamine (A81-724)

**CONFIDENTIAL**  
**ABBT0578020**

WELLCOME TRUST PRODUCTS R&D  
GENERAL CAPITAL EXPENSE REPORT  
Annualistic (A87-51)

	MONTHLY RESULTS												YTD				YEAR-END	
	Jan	Feb	March	Actual	Actual	July	June	Aug	Sept	Oct	Nov	Dec	Total	Approved YTD	Year	Proj. Year-End	Approved UPDATE	Var
Discovery	1	3	16	8	7	4	23	33	17	20	24	133	289	216	(73)	289	(525)	
Process Chemistry	134	198	116	82	91	67	59	91	130	299	276	90	1,933	1,108	1,633	1,108	...	
Drug Safety	15	21	7	19	36	32	10	9	3	14	22	18	206	1,419	206	1,419	1,213	
Metabolism	1	1	1	5	3	2	2	1	6	13	3	38	1,036	10,18	38	1,056	1,018	
Toxicology/Pathology	..	..	..	..	..	..	..	5	26	30	..	9	70	205	135	70	205	135
Comparative Medicine	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Medical Affairs	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Outcomes Res/Admin	5	5	5	5	5	5	4	5	5	5	5	5	59	49	(10)	59	49	(10)
Medical Services	5	5	5	5	5	5	4	5	5	5	5	5	59	49	(10)	59	49	(10)
Phase-I Center	1	2	1	1	1	1	3	1	5	2	7	1	19	145	126	19	145	126
Clinical	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
ACPRU - Direct	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Development Operations	16	12	34	17	22	24	26	15	11	10	12	15	214	604	390	214	604	390
Data Management	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Biostatistics	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
International Manpower	205	205	205	499	324	211	212	359	(155)	361	188	2,825	4,952	2,127	2,825	4,952	2,127	
Grants	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
International Directors	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Venture Management	117	95	234	131	82	130	149	164	88	168	176	68	1,702	1,473	(229)	1,702	1,473	(229)
PARD	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Regulatory/R&C	75	125	212	164	203	129	179	191	210	229	218	173	2,108	2,965	857	2,108	2,965	857
Research QA	1	8	38	27	15	17	20	9	30	36	16	15	232	351	119	232	351	119
Strategic Scientific Operation	..	2	2	2	2	2	1	2	2	1	1	1	19	0	(19)	19	0	(19)
Investigational Drug QA	5	(2)	8	8	11	..	13	11	7	9	11	78	150	72	78	150	72	
SPD	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
License/Pmt/Royalty	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Other	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Judgment	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
LU	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Total Global	579	679	878	966	805	648	712	892	1,015	643	1,158	725	-9,700	15,062	5,362	9,700	15,062	5,362

COMMENTS

CONFIDENTIAL  
ABBT0578021

PHARMA PROJECT STATUS  
Report Period (AB-173)

	PROJECT RESULTS												YTD			YEAR-END		
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	Total	Proj.	Approved	Approved	Approved	
	1	2	3	4	5	6	7	8	9	10	11	12	YTD	Year End	Upd.	Yr.	Yr.	
Discovery	141	203	166	133	161	101	1	2	1	1	3	1	914	1213	299	914	1213	
Process Chemistry	501	536	373	227	182	50	38	31	21	(1)	1	110	2089	2127	38	2089	2127	
Drug Safety	47	74	62	49	34	8	2	1	2	1	4	20	304	663	59	304	663	
Metabolism	6	6	8	2	4	42	4	3	2	1	5	6	88	419	331	88	419	
Toxicology/Pathology	30	26	44	17	23	14	10	13	12	7	14	(140)	79	(25)	(95)	(95)		
Comparative Medicine	12	12	12	13	12	13	12	13	22	13	12	(125)	21	(13)	21	(13)		
Medical Affairs	57	56	56	57	57	56	57	57	58	57	56	(454)	168	(1)	168	(1)		
Outcomes Res/Adm	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Medical Services	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Phase-i Center	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Clinical	25	45	3	(64)	5	3	105	12	40	13	8	17	200	351	15	200	351	
ACPRU - Direct	—	—	38	66	56	17	(80)	10	3	11	6	139	98	(41)	139	98		
Development Operations	99	149	188	114	163	98	97	90	59	82	57	35	1231	1232	1	1231	1232	
Data Management	56	45	59	65	91	70	65	98	51	53	71	61	785	629	(156)	785	629	
Biostatistics	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
International Manpower	1,347	1,831	3,512	86	...	1	...	75	13	13	(7)	(6)	(1,959)	(296)	1,482	1,778	(296)	
Grants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
International Directors	323	323	323	323	323	323	323	323	323	323	222	226	3,678	5,054	1,376	3,678	5,054	
Venture Management	321	402	360	484	272	129	101	612	(484)	47	69	35	2,368	2,422	—	2,308	2,422	
PARD	20	(20)	38	94	27	10	5	(174)	(174)	(61)	(61)	(61)	305	(1)	305	(1)	305	
Regulatory (RIC)	28	61	67	22	74	23	33	14	2	10	22	(5)	35	493	458	35	458	
Research QA	6	3	2	3	4	3	3	3	3	1	3	4	409	132	(278)	409	132	
Strategic Scientific Operation	10	23	(33)	25	9	22	3	6	27	237	43	35	—	—	—	—	—	
Investigational Drug QA	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
SPD	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
License Pmt/Royalty	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Other	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Judgment	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
U	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Total Global	3,419	3,815	(1,804)	1,835	1,578	1,011	636	2,356	1,514	665	865	(2,233)	13,856	17,044	3,187	13,856	17,044	

COMMENTS

CONFIDENTIAL  
ABBTO578022



R0025

COMprehensive Project Accounting System  
DINGII -- Project Detail - December, 2002

**CONFIDENTIAL**  
**ABBT0578023**

**COMprehensive Project Accounting SyStem**  
**DINGH -- Project Detail - December, 2002**

Page 2

Project Code	Project	Ben Code	Class Tax Code	Div Code	Dept Code	Cost/FEMP Code	Cost/Employee Description	Current Hours	Current Cost	YTD Hours	YTD Cost
13010	ABT-594 (CCM) Basic Program	G0	2	Q	R4P1	387980	VILLALOHO, BENITA Department R4P1 Total:	0.00	0.00	35.00	4,544.40
							HILYER, ERSKINE JAYARAMAN, SIVYAMALA MYERS, THOMAS	0.00	0.00	132.00	17,138.88
					R4P7	157000		0.00	0.00	20.00	2,594.80
					R4P7	532860		0.00	0.00	8.00	1,038.72
					R4P7	137480		0.00	0.00	208.50	27,071.64
							Department R4P7 Total:	0.00	0.00	236.50	30,707.16
					R4R2	255000	ALFANO, NICK KRUMDICK, ORVILLE	0.00	0.00	5.00	625.00
					R4R2	409870		0.00	0.00	6.00	750.00
							Department R4R2 Total:	0.00	0.00	11.00	1,375.00
							Division 47 Total:	0.00	0.00	379.50	49,221.64
52	R431	471990	HAN, LIXIN LIN, C					0.00	0.00	423.28	
	R431	446440					Department R431 Total:	0.00	0.00	8.00	8446.56
	R433	318060	LANDWER, KATHERINE LEWIS, SHAWN				LANDWER, KATHERINE LEWIS, SHAWN	0.00	0.00	0.50	47.87
	R433	C093816	NEIMAN, MICHELLE				NEIMAN, MICHELLE	0.00	0.00	16.50	1,579.72
	R433	C093949	PROUTY, GLENN				PROUTY, GLENN	0.00	0.00	3.50	335.09
	R433	218250						0.00	0.00	0.50	47.87
	R433		CHIU, WENZI DEA'ION, ROGER				CHIU, WENZI DEA'ION, ROGER	0.00	0.00	82.50	8,730.15
	R436	619830	THOMAS, JAMES				THOMAS, JAMES	4.00	4.00	423.28	9,000.00
	R436	013080								9.00	952.38
	R436	330690								10.105.81	
							Department R436 Total:	4.00	423.28		
							Division 52 Total:	4.00	423.28	12,962.92	
53	R44F	598960	FRANZ, LISA JENSEN, MICHELLE				JENSEN, MICHELLE	0.00	0.00	28.00	3,966.48
	R44F	095570	SMALI, MARIA				SMALI, MARIA	0.00	0.00	6.00	849.96
	R44F	319650						0.00	0.00	7.00	991.62
							Department R44F Total:	0.00	0.00	41.00	5,808.06
	R44K	023870	NGUYEN, HAI GUICL, D				NGUYEN, HAI GUICL, D	0.00	0.00	1.00	120.82
	R4QE	176650								13.00	1,841.58
							Division 53 Total:	0.00	0.00	55.00	7,770.46
							INT'L SUPPORT	0.00	-4,166.66	0.00	0.00
56	R421	1921830	DOMESTIC GRANTS SHULTIS, BONNIE				DOMESTIC GRANTS SHULTIS, BONNIE	0.00	0.00	0.00	-6,272.30
59	R49G	G9910	BURT, DAVID				BURT, DAVID	0.00	0.00	7.00	522.41
62	R461	0161300	CHU, WENZI				CHU, WENZI	0.00	0.00	50.00	5,291.00
64	R43V	422260	HOSMANE, B				HOSMANE, B	0.00	0.00	11.00	1,164.02
	R43V	619830	LOCKE, C				LOCKE, C	0.00	0.00	3.00	952.38
	R43V	C090322	ZIANG, Y				ZIANG, Y	11.00	1,164.02	19.00	317.46
	R43V	130430								2,010.58	
	R43V	392290									
							Department R43V Total:	11.00	1,164.02	92.00	9,735.44
										65.00	7,840.00
	R4PK	401290	DUTTA, SANDEEP GRANNEMAN, RICHARD				GRANNEMAN, RICHARD	8.00	681.50	6.00	681.60
	R4PK	261690	LEE, LILLIAN				LEE, LILLIAN	0.00	0.00	16.00	1,817.60
	R4PK	398290	SCIWEITZER, SARAH				SCIWEITZER, SARAH	25.00	2,840.00	14.00	15,904.00
	R4PK	369060								227.00	25,787.20
							Department R4PK Total:	39.00	4,430.40	319.00	35,322.64
							Division 64 Total:	50.00	5,594.42	319.00	

CONFIDENTIAL  
ABBT0578024

R0025

**COMprehensive Project Accounting System**  
**DINGII – Project Detail - December, 2002**

Page 3

Project Code	Project	Dept	Div	Cost/Emp Code	Cost/Emp Code	Current Hours	Current Cost	YTD Hours	YTD Cost
143010	ABT-394 (CCM) Base Program	G0	2	Q	65	R420	313830 323310	16.00 0.00	2,196.00 0.00
							COLLICOTT, MARILYN VENTURE ABSORPTION FEIGE, CAROL KACOS, CATHERINE MATALONIS, ALDONA	16.00 0.00 0.00 0.00 0.00	2,196.00 0.00 0.00 0.00 0.00
							Department R420 Total:	16.00	33.00
							CHIRA, T RIPPA, JEANNETTE	0.00 0.00	24.00 9.00
							Department R420 Total:	16.00	33.00
							FEIGE, CAROL	0.00	0.00
							Division 65 Total:	16.00	448.00
							HARMAN, WILLINEY BANDERA, GISELA BENTlage, KEITH REDMAN, PAMELA	0.00 0.00 0.00 0.00	4.00 0.00 0.00 0.00
							Department R492 Total:	0.00	0.00
							Project 143010 Total:	101.50	1,814,143.36
							COSNER, SANDRA MISC EXP COOKE, MARCIA DROBNICK, MARK TURK, PATRICIA M WRIGHT, JOSEPH	0.00 0.00 0.00 0.00 0.00 0.00	0.00 0.00 0.00 0.00 0.00 0.00
							Department 0421 Total:	0.00	0.00
							MURAOKA, LEE	0.00	0.00
							Division 20 Total:	0.00	0.00
							KALLAL, THOMAS ORR, MICHAEL	0.00 0.00	7.00 20.00
							Department R44F Total:	0.00	0.00
							FRANZ, LISA JENSEN, MICHELLE ORR, MICHAEL	3.00 1.00 0.00	27.00 424.98 0.00
							Department R4QE Total:	4.00	566.64
							Division 53 Total:	4.00	566.64
							Project 143030 Total:	4.00	566.64
							Grand Total:	105.00	8,302.64
									1,155.25
									1,409,082.62

**CONFIDENTIAL**  
**ABBT0578025**

EE

2003

**Global Pharmaceutical Research & Development**  
**Global Development Project Expense Report**  
**Project Group: ABT-492 Quinolones**

**Site: Global - All Sites****December, 2003 (\$000's)**

Update	2003 Actual	2003 Actuals	2003 Actuals	Act vs Update											
YTD	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD	YTD	YTD
W05 - WW Therapeutic Discovery	551	118	112	126	66	36	24	10	15	6	4	2	1	518	33
W10 - WW Pre-clinical Safety	269	88	64	70	45	26	38	45	21	9	15	18	9	449	(18)
W25 - WW Phase I Center	101	9	11	18	12	5	10	5	3	17	10	13	13	126	(25)
W30 - WW Clinical Operations	0	0	0	0	0	373	0	0	0	0	0	0	0	0	373
W44 - WW Scientific Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(33)
W45 - WW Global Project Teams	2,029	175	107	131	157	144	145	129	144	133	134	126	170	1,696	333
W50 - WW Project Services	200	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W55 - WW Pharm Analytical R&D	285	151	54	69	32	30	26	27	42	8	4	11	6	461	(176)
W57 - WW Global Drug Supply Mgmt	72	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W60 - WW Regulatory Affairs	59	7	3	5	5	5	5	5	5	5	5	5	5	5	59
W65 - WW GPCO Administration	0	1	1	2	2	0	1	2	4	1	2	0	3	19	(19)
W70 - WW Shared Services	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W75 - WW Services Sold	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total WW</b>	<b>4,513</b>	<b>697</b>	<b>592</b>	<b>479</b>	<b>757</b>	<b>341</b>	<b>175</b>	<b>1,362</b>	<b>315</b>	<b>230</b>	<b>224</b>	<b>232</b>	<b>(1,342)</b>	<b>4,061</b>	<b>452</b>

**COMMENTS**

A103MT  
A103MT  
A103MT  
A103MT  
A103MT  
A103MT

**Global Pharmaceutical Research & Development**  
**Global Development Project Expense Report**  
**Project Group: ABT-510 (TSP Peptide)**  
**Site: Global - All Sites**  
**December, 2003 (000's)**

Update	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	Act vs. Update YTD
	YTD	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD	
W05 - WW Therapeutic Discovery	372	27	27	46	49	48	59	48	58	56	52	31	19	520	(147)
W10 - WW Manufacturing	3,063	124	589	200	165	102	227	281	213	251	310	326	448	3,214	(151)
W15 - WW Pre-clinical Safety	200	10	11	8	9	11	4	8	15	13	8	16	19	132	(122)
W20 - WW Clinical Trials	266	0	0	0	0	73	0	0	0	0	0	0	0	0	(125)
W25 - WW Phase I Center	206	0	0	0	0	0	0	0	0	0	0	0	0	0	(122)
W30 - WW Manufacturing	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(134)
W35 - WW Scientific Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(135)
W40 - WW Project Management	2,632	213	180	232	239	244	221	211	186	269	221	242	283	2,759	(73)
W45 - WW Global Project Teams	1,286	167	261	357	267	138	232	146	75	122	386	308	232	2,696	(1,410)
W50 - WW Pharm Analytical R&D	1,286	167	261	357	267	138	232	146	75	122	386	308	232	2,696	(1,410)
W55 - WW Clinical Research	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(1,410)
W60 - WW Regulatory Affairs	107	1	17	9	9	9	9	9	9	9	9	9	9	9	(1,410)
W65 - WW GPCD Administration	54	3	2	5	11	7	5	0	3	7	8	7	5	63	(9)
W70 - WW Services Sold	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(9)
<b>TotalWW</b>	<b>17,633</b>	<b>867</b>	<b>1,398</b>	<b>1,442</b>	<b>1,490</b>	<b>1,128</b>	<b>1,395</b>	<b>1,687</b>	<b>1,462</b>	<b>1,179</b>	<b>1,804</b>	<b>2,755</b>	<b>2,088</b>	<b>18,477</b>	<b>(845)</b>

COMMENTS  
CNKNAG  
CNKNAG  
CNKNAG  
CNKNAG  
CNKNAG  
CNKNAG

**Global Pharmaceutical Research & Development  
Global Development Project Expense Report  
Project Group: ABT-627 (atrasentan)**

COMMENTS  
CNKNN  
CNKNN  
CNKNN  
CNKNN  
CNKNN  
CNKNN

Global Pharmaceutical Research & Development  
 Global Development Project Expense Report  
 Project Group: ABT-724 (Dopamine-4 Agonist)

Site: Global - All Sites

December, 2003 (000's)

Update YTD	2003 Actual	2003 Actuals	Act vs. Updates YTD													
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD			
W05 - WW Therapeutic Discovery	0	9	15	(2)	12	10	1	10	6	9	0	0	4	75	(75)	
W06 - WW Clinical R&D	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W15 - WW Pre-clinical Safety	331	33	20	44	49	18	99	13	4	5	31	1	2	318	13	
W25 - WW Phase I Center	57	1	1	1	6	3	0	4	0	0	0	0	1	17	40	
W35 - WW Scientific Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W40 - WW Project Management	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W45 - WW Global Project Teams	75	0	0	0	0	0	0	0	0	0	0	0	0	0	0	75
W50 - WW Clinical Trials	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W55 - WW Pharm. Analytical R&D	90	21	5	10	5	4	2	0	1	1	1	0	0	51	40	
W57 - WW Standardization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W60 - WW Regulatory Affairs	61	1	(1)	0	0	0	0	0	0	0	0	0	0	0	0	61
W65 - WW Manufacturing	72	0	0	0	0	0	0	0	0	0	0	0	0	0	0	72
W67 - WW GPCD Administration	6	4	1	0	0	1	0	0	0	0	0	0	0	0	0	2
W70 - WW Services Delivered	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W75 - WW Services Sold	752	301	120	111	79	43	107	39	14	22	33	4	(38)	834	(82)	
ToWW																

## COMMENTS

UR01DP  
 UR10P  
 UR01DP  
 UR10P  
 UR01DP  
 UR10P

Global Pharmaceutica... Research & Development  
 Global Development Project Expense Report  
 Project Group: ABT-751 (Eisai Anti-Mitotic)

Site: Global - All Sites

December, 2003 (000's)

Update YTD	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	2003 Actuals	Act vs. Update YTD
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD	YTD	YTD	YTD
W05 - WW Therapeutic Discovery	149	4	12	12	8	21	8	18	37	19	12	36	39	228	(79)	
W06 - WW Manufacturing	118	11	11	11	11	11	11	11	11	11	11	11	11	11	11	(128)
W15 - WW Pre-clinical Safety	676	27	59	74	87	115	59	63	72	66	70	64	66	805	(128)	
W25 - WW Phase I Center	278	0	12	8	28	30	2	20	5	11	2	14	20	162	127	
W35 - WW Scientific Operations	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	(1)
W40 - WW Project Management	118	11	11	11	11	11	11	11	11	11	11	11	11	11	11	(11)
W45 - WW Global Project Teams	2,121	170	144	186	191	195	177	169	157	215	177	193	234	2,208	(87)	
W50 - WW Clinical Services	1,255	125	125	125	125	125	125	125	125	125	125	125	125	1,255	1,255	
W55 - WW Pharm Analytical R&D	2,179	169	181	95	96	79	117	118	92	98	195	122	193	1,554	625	
W60 - WW Regulatory Affairs	76	0	13	6	6	6	6	6	6	6	6	6	6	6	6	(1)
W65 - WW GPCD Services	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	(122)
W67 - WW GPCD Administration	103	8	4	5	7	3	3	2	1	1	6	7	6	52	51	
W75 - WW Services Sold	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	(0)
<b>TotalWW</b>	<b>10,681</b>	<b>627</b>	<b>1,310</b>	<b>964</b>	<b>701</b>	<b>816</b>	<b>671</b>	<b>1,011</b>	<b>1,095</b>	<b>1,006</b>	<b>1,385</b>	<b>1,341</b>	<b>82</b>	<b>11,007</b>	<b>(326)</b>	

## COMMENTS

CNKNES  
 CNKNES  
 CNKNES  
 CNKNES  
 CNKNES  
 CNKNFS

Global Pharmaceutical Research & Development  
 Global Development Project Expense Report  
 Project Group: ABT-773 Katolide

Site: Global - All Sites

December, 2003 (\$'000's)

Update YTD	2003 Actuals Jan	2003 Actuals Feb	2003 Actuals Mar	2003 Actuals Apr	2003 Actuals May	2003 Actuals Jun	2003 Actuals Jul	2003 Actuals Aug	2003 Actuals Sep	2003 Actuals Oct	2003 Actuals Nov	2003 Actuals Dec	2003 Actuals YTD	Act vs. Update YTD
W01 - WW Project Control	0	1	2	0	0	0	0	1	1	0	1	0	0	(6)
W05 - WW Therapeutic Discovery	54	14	20	7	7	2	8	2	1	1	2	1	1	65 (11)
W06 - WW Pre-clinical Safety	11	11	21	16	19	9	2	3	0	0	0	2	4	90 (79)
W21 - WW Global Medical Affairs	0	0	0	0	4	0	0	0	0	0	0	0	4	(4)
W25 - WW Phase I Center	792	41	29	32	24	12	24	7	9	6	4	3	203	589
W32 - WW Clinical Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W60 - WW Scientific Operations	370	33	20	25	29	27	27	24	27	25	24	32	318	52
W65 - WW Global Project Teams	59	11	(1)	5	5	5	5	5	5	5	5	5	59	59
W66 - WW Clinical Trials	38	3	1	6	7	2	1	1	4	2	3	3	39	(1)
W67 - WW GPCD Administration	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W75 - WW Services Sold	1,702	201	199	(284)	199	195	(1,366)	196	47	(505)	77	46	68	(929) 2,631
Total														

## COMMENTS

A102MC  
 A102MC  
 A102MC  
 A102MC  
 A102MC  
 A102MC

FF







Global Pharmaceutical Research & Development  
Global Development Project Expense Report  
Project Group: ABT-773 Ketolide

Site: Global - All Sites

December, 2004 (000's)

	Update M12YTD	Actuals Jan	Actuals Feb	Actuals Mar	Actuals Apr	Actuals May	Actuals Jun	Actuals Jul	Actuals Aug	Actuals Sep	Actuals Oct	Actuals Nov	Actuals Dec	Actuals M12YTD	Act vs. Update M12YTD
W01 - WW Project Costs	0	1	1	1	1	1	1	1	1	1	1	1	1	1	28
W05 - WW Therapeutic Discovery	28	1	0	0	0	0	0	0	0	0	0	0	0	0	1
W40 - WW Project Costs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W15 - WW Pre-clinical Safety	0	0	0	2	5	0	1	0	0	0	0	1	0	11	(11)
W20 - WW Global Project Costs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W25 - WW Phase I Center	7	0	0	0	1	0	0	0	0	0	0	0	0	0	5
W40 - WW Department Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W35 - WW Scientific Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W40 - WW Scientific Services	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W45 - WW Scientific Staffing	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W50 - WW Project Grants	75	1	0	19	1	0	0	0	0	0	0	0	0	0	34
W55 - WW Pharm Analytical R&D	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W57 - WW Global Project Management	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W60 - WW Regulatory Affairs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W65 - WW Quality Assurance	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W67 - WW GPOD Administration	0	3	1	0	1	1	1	1	1	1	1	1	1	10	(10)
W70 - WW Global Licensing & New Business	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W75 - WW Services Sold	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TotWW	423	14	12	30	71	14	8	23	49	(43)	11	44	30	260	163

Update Year	RunRate Year	RunRate vs Upd Year	Comments
W01 - WW Project Costs	0	0	A102MC
W05 - WW Therapeutic Discovery	28	1	A102MC
W40 - WW Project Costs	0	0	A102MC
W15 - WW Pre-clinical Safety	0	11	A102MC
W20 - WW Project Costs	0	0	A102MC
W25 - WW Phase I Center	7	1	A102MC
W40 - WW Department Operations	0	0	A102MC
W45 - WW Scientific Services	0	0	A102MC
W50 - WW Project Teams	75	109	(34)
W55 - WW Clinical Trials	0	0	(32)
W57 - WW Project Management	0	0	(31)
W60 - WW Regulatory Affairs	0	0	(68)
W65 - WW Quality Assurance	0	0	(10)
W67 - WW GPOD Administration	0	10	(10)
W70 - WW Global Licensing & New Business	0	0	(10)
W75 - WW Services Sold	0	0	(10)
TotWW	423	260	163

FC  
G

CONFIDENTIAL  
ABBT0578036

Global Pharmaceutical | Arch & Development  
Global Development Project Expense Report  
Project Group: ABT-510 (TSP Peptide)  
Site: Global - All Sites  
December, 2005 (000's)

Plan N12YTD	Actuals Jan		Actuals Feb		Actuals Mar		Actuals Apr		Actuals May		Actuals Jun		Actuals Jul		Actuals Aug		Actuals Sep		Actuals Oct		Actuals Nov		Actuals Dec		Act vs Plan N12YTD	
	Actuals	Actuals	Actuals	Actuals																						
W01 - VWL Project Costs	0	0	0	0	0	0	0	0	22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W02 - VWV Therapeutic Discovery	0	76	68	56	122	126	64	121	35	64	63	34	45	993	0	0	0	0	0	0	0	0	0	0	0	0
W07 - VWV Discovery IT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W10 - VWV Projects Research & Devt	0	311	412	53	670	649	770	496	515	538	295	181	170	5614	0	0	0	0	0	0	0	0	0	0	0	0
W13 - VWV GPO (ASIG)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W15 - VWV Pre-Clinical Development	972	469	483	536	628	426	283	320	519	285	214	439	326	4942	0	0	0	0	0	0	0	0	0	0	0	0
W20 - VWV Development Operations	397	56	70	136	73	81	77	42	64	47	53	59	35	793	0	0	0	0	0	0	0	0	0	0	0	0
W25 - VWV Experimental Medicine	592	51	49	52	46	52	31	8	15	20	42	58	22	443	0	0	0	0	0	0	0	0	0	0	0	0
W30 - VWV Life Cycle Management	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W35 - VWV Clinical Project Teams	1,410	78	0	740	326	38	450	43	127	220	322	323	181	2,647	0	0	0	0	0	0	0	0	0	0	0	0
W40 - VWV Finance & Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W45 - VWV Medical Affairs	65	21	22	32	19	16	25	2	0	25	11	10	11	263	0	0	0	0	0	0	0	0	0	0	0	0
W46 - VWV Medical Services	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W47 - VWV Quality Assurance	225	33	45	53	33	44	20	35	40	25	28	26	26	419	0	0	0	0	0	0	0	0	0	0	0	0
W48 - VWV Clinical Grants	282	146	146	0	0	0	0	0	0	0	0	0	0	0	600	0	0	0	0	0	0	0	0	0	0	0
W50 - VWV Development Management	56	0	1	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W55 - VWV Regulatory Affairs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W56 - VWV Human Resources	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W58 - VWV PRG IT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W65 - VWV Services Purchased	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W68 - VWV Services Sold	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W69 - VWV Other Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W88 - VWV ECO Estimates	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W91 - Japan Development	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Total VWV	3,958	1,243	1,297	2,249	1,317	1,441	1,735	1,056	1,469	1,223	993	1,267	838	16,136	115,574											

2005

Global Pharmaceutical R&D & Development  
 Global Development Project Expense Report  
 Project Group: ABT-527 (Itraconazole)  
 Site: Global - All Sites  
 December, 2005 (000's)

Plan M12YTD	Actuals Jan		Actuals Feb		Actuals Mar		Actuals Apr		Actuals May		Actuals Jun		Actuals Jul		Actuals Aug		Actuals Sep		Actuals Oct		Actuals Nov		Actuals Dec		Actuals M12YTD			
	Actuals	Actuals	Actuals	Actuals																								
W001 - WW LU Project Costs	0	1	2	2	1	2	2	2	1	2	2	2	2	2	2	2	2	2	3	6	6	6	6	6	6	26	25	
W005 - WW Therapeutic Discovery	2,853	63	94	86	31	56	71	57	153	61	53	53	26	..	635	635	635	635	0	0	0	0	0	0	0	0	0	
W007 - WW Discovery IT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W010 - WW Process Research & Devr	1,191	21	13	13	4	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,145	
W013 - WW GPO (ABC)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W015 - WW Pre-Clinical Development	6,625	537	748	801	590	596	583	589	575	565	298	411	536	696	696	696	696	696	696	696	696	696	696	696	696	696		
W020 - WW Development Operations	3,072	201	162	221	159	245	311	213	258	274	192	192	175	2604	2604	2604	2604	2604	2604	2604	2604	2604	2604	2604	2604	2604	2604	
W025 - WW Experimental Medicine	834	30	36	32	18	36	32	18	23	5	44	20	3	304	304	304	304	304	304	304	304	304	304	304	304	304	304	
W030 - WW Life Cycle Management	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W035 - WW Clinical Project Teams	12,606	251	0	1,593	1,056	294	1,185	54	508	862	865	1,625	225	9,75	9,75	9,75	9,75	9,75	9,75	9,75	9,75	9,75	9,75	9,75	9,75	9,75	9,75	
W040 - WW Financials & Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W045 - WW Medical Affairs	1,092	72	96	92	160	107	107	107	107	107	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
W048 - WW Medical Services	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W051 - WW Quality Assurance	1,018	51	57	60	64	102	34	55	49	29	33	33	27	593	593	593	593	593	593	593	593	593	593	593	593	593	593	
W052 - WW Clinical Grants	20,315	1,873	1,873	1,870	2,038	1,561	1,539	2,361	1,821	1,539	1,393	2,613	1,587	21,989	21,989	21,989	21,989	21,989	21,989	21,989	21,989	21,989	21,989	21,989	21,989	21,989	21,989	
W050 - WW Development Management	28	6	1	1	1	27	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W055 - WW Regulatory Affairs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W058 - WW Human Resources	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W060 - WW PPG IT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W065 - WW Services Purchased	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W068 - WW Services Sold	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W071 - WW Other Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W078 - WW ECO Estimates	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
W079 - Japan Development	1,723	121	85	125	92	145	68	68	8	0	283	110	70	84	1,04	1,04	1,04	1,04	1,04	1,04	1,04	1,04	1,04	1,04	1,04	1,04	1,04	1,04
Total WW	51,358	3,132	4,883	4,329	3,062	4,007	3,123	3,389	3,651	2,968	5,264	3,271	44,557	6,791														

CONFIDENTIAL  
 ABBT0578037

Global Pharmaceutical - Research & Development  
 Global Development Project Expense Report  
 Project Group: ABT-751 (Eisai Anti-Mitotic)  
 Site: Global - All Sites  
 December, 2005 (000's)

Plan	Actuals		Actuals		Actuals		Actuals		Actuals		Actuals		Actuals		Actuals	
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	M12YTD	W12YTD		
W01 - WW LU Project Costs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W05 - WW Therapeutic Discovery	0	36	35	39	24	46	52	44	52	50	51	152	170	140	0	0
W07 - WW Discovery IT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W10 - WW Process Research & Dev	2,541	2	14	185	13	47	147	164	43	22	36	76	74	824	1,715	0
W13 - WW GPO (ABC)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W15 - WW Pre-Clinical Development	2,011	155	245	335	281	414	467	356	491	322	48C	472	421	4,449	0	0
W20 - WW Development Operations	934	31	190	75	29	71	85	46	53	31	41	98	64	731	203	0
W25 - WW Experimental Medicine	702	27	53	43	37	25	41	31	55	47	13	44	28	442	252	0
W30 - WW Life Cycle Management	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W35 - WW Clinical Project Teams	4,445	26	0	558	144	94	440	25	184	242	260	661	363	3,138	1,247	0
W40 - WW Finance & Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W45 - WW Historical Affairs	37	9	9	6	6	7	5	7	0	15	2	6	6	72	1	0
W46 - WW Medical Services	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W47 - WW Quality Assurance	677	5	40	43	17	5	4	6	16	13	15	25	9	195	481	0
W49 - WW Clinical Grants	1,066	231	331	102	81	25	7	7	113	113	113	113	113	1,669	1,113	0
W50 - WW Development Management	82	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W53 - WW Regulatory Affairs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W55 - WW Human Resources	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W56 - WW PRG, IT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W58 - WW Services Purchased	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W60 - WW Services Sold	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W65 - WW Other Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W68 - WW ECO Estimates	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
W91 - Japan Development	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>TotalWW</b>	<b>12,435</b>	<b>627</b>	<b>638</b>	<b>1,616</b>	<b>853</b>	<b>791</b>	<b>1,259</b>	<b>624</b>	<b>901</b>	<b>838</b>	<b>1,072</b>	<b>1,646</b>	<b>1,248</b>	<b>12,321</b>	<b>174</b>	

CONFIDENTIAL  
ABBTO578038

FO

**UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF MASSACHUSETTS**

JOHN HANCOCK LIFE INSURANCE	)	
COMPANY, JOHN HANCOCK VARIABLE	)	
LIFE INSURANCE COMPANY, and	)	
MANULIFE INSURANCE COMPANY (f/k/a	)	
INVESTORS PARTNER LIFE INSURANCE	)	
COMPANY),	)	CIVIL ACTION NO. 05-11150-DPW
Plaintiffs,	)	
	)	
v.	)	
	)	
ABBOTT LABORATORIES,	)	
	)	
Defendants,	)	

**ABBOTT LABORATORIES' AMENDED RESPONSES AND OBJECTIONS  
TO PLAINTIFFS' SECOND SET OF INTERROGATORIES**

Defendant Abbott Laboratories ("Abbott"), by its undersigned counsel and pursuant to Rule 33 of the Federal Rules of Civil Procedure and Local Rules, hereby responds and objects the Second Set of Interrogatories of Plaintiffs John Hancock Life Insurance Company, John Hancock Variable Life Insurance Company, and Investors Partner Life Insurance Company's (collectively, "Hancock").

**GENERAL OBJECTIONS AND RESPONSES**

The following General Objections and Responses apply to each and every one of the numbered interrogatories below, and the General Objections and Responses shall be deemed continuing as to each interrogatory and are not waived, or in any way limited, by the specific objections and answers to any individual interrogatory.

1. Abbott objects to the "Definitions and Instructions" set forth in Hancock's interrogatories, as well as the interrogatories themselves, to the extent that

Hancock seeks to require Abbott to provide information beyond that required by the Federal Rules of Civil Procedure or Local Rules of the Court.

2. Abbott objects to each Interrogatory to the extent that it seeks information or documents protected by the attorney-client privilege, the work product doctrine, or any other applicable privileges.

3. Abbott objects to each and every Interrogatory to the extent that it is overly broad in scope or time and unduly burdensome.

4. Abbott objects to each and every Interrogatory to the extent that it calls for information that is not relevant to any of the claims or defenses in this litigation.

5. Abbott objects to each and every Interrogatory to the extent that it calls for information outside of Abbott's possession, custody, or control.

6. To the extent that Abbott responds to specific Interrogatories to which it has objected, Abbott's objections are not waived by the furnishing of such information and Abbott reserves the right to maintain such objections with respect to any additional information.

7. To the extent that Abbott responds to a specific Interrogatory, Abbott does not admit Plaintiffs' characterizations of any documents, facts, theories, or conclusions.

8. To the extent that Abbott responds to a specific Interrogatory, Abbott does not admit the relevance of such information to the subject matter of this litigation. Further, by responding to Hancock's interrogatories, Abbott is not waiving any applicable privileges nor shall the inadvertent disclosure of any privileged information operate as a waiver of any applicable privilege or immunity from discovery.

9. The responses to these Interrogatories are based on information currently known to Abbott and its current employees, and Abbott expressly reserves the right to supplement its responses to these Interrogatories with further additional information and documents as such information and documents become available to Abbott in the course of this litigation.

10. Except where specifically indicated below, the individuals identified in response to these interrogatories are all current or former employees of Abbott to be contacted only through counsel of record for Abbott herein.

11. Abbott objects to these interrogatories on the ground that in total, including all discrete subparts, they exceed the total number of interrogatories permitted by the Federal Rules of Civil Procedure, Local Rules and any Orders entered by the Court in this case.

Subject to these General Objections and Responses, and without waiving the same, Abbott states as follows:

**SPECIFIC OBJECTIONS AND RESPONSES**

**15. Please state Abbott's actual spending on Program Related Costs for each Program Compound during each year of the four-year Program Term (i.e., 2001 through and including 2004), and during the subsequent year commencing immediately after the end of the Program Term (i.e., 2005).**

**Response:** Abbott specifically objects to this interrogatory on the grounds that it is overly broad and unduly burdensome. Subject to these specific objections and its General Objections and Responses, and without waiving them, Abbott states that its actual spending on Program Related Costs for each of the Program Compounds for the period 2001-2005 is set forth below:

Number	Name	2001	2002	2003	2004	2005	Total
ABT-100	FTI	3.6	2.4	0.0	0.0	0.0	<b>6.0</b>
ABT-492	Quinolone	20.1	28.2	4.1	0.0	0.0	<b>52.4</b>
ABT-510	TSP #1	8.8	12.3	18.5	23.6	16.2	<b>79.4</b>
ABT-518	MMPI	3.7	0.0	0.0	0.0	0.0	<b>3.7</b>
ABT-594	Neuro Pain	7.8	1.4	0.0	0.0	0.0	<b>9.2</b>
ABT-627	Altrasentan Base	34.1	48.1	50.7	38.4	38.7	<b>210.0</b>
ABT-627	Altrsntan Hormone Naïve Prostate Cancer	0.0	1.2	2.5	2.3	3.3	<b>9.3</b>
ABT-627	Japan	0.0	0.1	0.2	1.5	1.5	<b>3.3</b>
ABT-627	Non-Prostate Cancers	0.0	0.0	0.2	1.0	0.9	<b>2.1</b>
ABT-724	Dopamine 4 Agonist	3.2	5.5	0.8	0.0	0.0	<b>9.5</b>
ABT-751	Anti-Mitotic	6.5	9.6	11.0	13.5	12.3	<b>52.9</b>
ABT-773	Base	80.3	13.8	(0.9)	0.3	0.0	<b>93.5</b>
ABT-773	Japan	1.4	1.9	0.0	0.0	0.0	<b>3.3</b>
	<b>Total</b>	<b>169.5</b>	<b>124.5</b>	<b>87.1</b>	<b>80.6</b>	<b>72.9</b>	<b>534.6</b>

**Amended Response:** Abbott specifically objects to this interrogatory on the grounds that it is vague, ambiguous, overly broad and unduly burdensome. Subject to these specific objections and its General Objections and Responses, and without waiving them, Abbott responds as follows:

After meeting and conferring with Hancock, Abbott agreed to amend its response to this interrogatory to state its actual monthly spending on each of the Program Compounds in January, February, and March 2001. In the course of preparing its amended interrogatory response, Abbott discovered some inadvertent errors in its original response. Abbott's corrected actual calendar year spending on Program Related Costs for each of the Program Compounds for the period 2001-2005 is set forth below:

Number	Name	2001	2002	2003	2004	2005	Total
ABT-100	FTI	9.2	2.4	0.0	0.0	0.0	<b>11.6</b>
ABT-492	Quinolone	23.1	32.8	4.1	0.0	0.0	<b>60.0</b>
ABT-510	TSP #1	8.8	12.8	18.5	23.6	16.1	<b>79.8</b>

ABT-518	MMPI	3.7	0.0	0.0	0.0	0.0	<b>3.7</b>
ABT-594	Neuro Pain	7.8	1.4	0.0	0.0	0.0	<b>9.2</b>
ABT-627	Altrasentan Base	34.1	51.8	53.6	43.4	44.6	<b>227.5</b>
ABT-627	Altrasentan Hormone Naïve	-	-	-	-	-	-
ABT-627	Prostate Cancer	-	-	-	-	-	-
ABT-627	Japan	-	-	-	-	-	-
ABT-627	Non-Prostate Cancers	-	-	-	-	-	-
ABT-724	Dopamine 4 Agonist	8.1	6.5	0.8	0.0	0.0	<b>15.4</b>
ABT-751	Anti-Mitotic	6.5	9.7	11.0	13.5	12.3	<b>53.0</b>
ABT-773	Base	80.8	13.9	(0.9)	0.3	0.0	<b>94.1</b>
ABT-773	Japan	-	-	-	-	-	-
	<b>Total</b>	<b>182.1</b>	<b>131.3</b>	<b>87.1</b>	<b>80.8</b>	<b>73.0</b>	<b>554.3</b>

Abbott's actual monthly expenditures on each Program Compound in 2001 are reflected in the Abbott expense reports attached hereto as Exhibit A. Please note that expenditures on the ED Program (ABT-724) are the sum of the expenditures reported on pages A-38 and B-4. Abbott also is producing concurrently with this amended interrogatory response expense reports reflecting the actual expenditures on each Program Compound from 2002 through 2005.

In addition to the expenditures that are listed above and in the attached expense reports, Abbott made management fee and/or milestone payments to Hancock in the amount of \$10 million in 2002, \$2 million in 2003, and \$2 million in 2004, which constitute Program Related Costs under Section 1.43 of the Research Funding Agreement.

**16. Please state whether any of the representations or warranties made by Abbott in Section 12.2 of the Research Funding Agreement were untrue or inaccurate in any way as of March 13, 2001.**

**Response:** Abbott specifically objects to this interrogatory on the grounds that it is grossly compound, overly broad and unduly burdensome. Because Section 12.2 of the Research Funding Agreement incorporates by reference nine other documents, containing hundreds of sentences, the task of determining whether any of the


representations or warranties made in Section 12.2 are “untrue” or “inaccurate” “in any way” is unduly burdensome. Moreover, if every sentence in Section 12.2 and the documents incorporated therein are considered representations and warranties, the request exceeds the number of interrogatories permitted (including subparts) in this litigation. Abbott also objects to this interrogatory because it seeks information protected from disclosure under the attorney-client privilege and attorney work product doctrine. This interrogatory seeks, *inter alia*, Abbott’s legal analysis and conclusions as to which statements contained in the numerous documents attached to the Agreement and incorporated into Section 12.2 constitute a representation or warranty and also whether or not any such representations or warranties were untrue or inaccurate in any way. As a result, this interrogatory cannot be answered without disclosing attorney work product and attorney-client privileged communications, and any response by Abbott would be intertwined with the mental impressions, conclusions, opinions, and legal theories of its counsel as a result of its investigation of the claims made by Hancock in this case. Finally, Abbott objects to this interrogatory on the ground that it attempts improperly to shift the burden of proof from Hancock to Abbott on Hancock’s claims in this case.

**17. If your answer to Interrogatory No. 16, *supra*, is anything other than an unqualified negative, please state in as much detail as reasonably possible which specific representations or warranties made by Abbott in Section 12.2 of the Research Funding Agreement were untrue or inaccurate as of March 13, 2001 and why.**

**Response:** Abbott incorporates by reference its response to Interrogatory No. 16.

ABBOTT LABORATORIES

By its attorneys



Eric J. Lorenzini

Jeffrey I. Weinberger (Admitted Pro Hac Vice)  
Gregory D. Phillips (Admitted Pro Hac Vice)  
Eric J. Lorenzini (Admitted Pro Hac Vice)  
Ozge Guzelsu (Admitted Pro Hac Vice)  
MUNGER, TOLLES & OLSON LLP  
355 South Grand Avenue, 35th Floor  
Los Angeles, CA 90071  
(213) 683-9100

and

Michael S. D'Orsi  
Peter E. Gelhaar (BBO #188310)  
Michael S. D'Orsi (BBO #566960)  
DONNELLY, CONROY & GELHAAR LLP  
1 Beacon St., 33rd Floor  
Boston, Massachusetts 02108  
(617) 720-2880

Dated: Aug. 3, 2007

**VERIFICATION**

I, Kenneth Stiles, state under penalties of perjury that: I am Assistant Controller for Global Pharmaceutical Research and Development at Abbott Laboratories ("Abbott"). I have read the foregoing responses to interrogatories and know the contents thereof; that said answers were prepared with the assistance and advice of counsel and employees of Abbott; that the responses set forth herein, subject to inadvertent or undiscovered errors, are based on and therefore necessarily limited by the records and information still in existence, presently collected and thus far discovered in the course of the preparation of these answers; that Abbott reserves the right to make any changes in the responses if it appears at any time that omissions or errors have been made therein or that more accurate information is available; and that, subject to the limitations set forth herein, the responses are true to the best of my knowledge, information and belief.

Interrogatory answers signed under the pains and penalties of perjury this  
3rd day of August, 2007.

Kenneth D. Stiles  
Kenneth Stiles

# **Exhibit A**

28-Jan-02  
PAGE A-11  
PHARMACEUTICAL PRODUCTS R&D  
GLOBAL DISCOVERY PROJECT EXPENSE REPORT  
FARNESYLTRANSFERASE

	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	MONTHLY RESULTS		YTD Total	Approved APU	YTD Var.	
													Jan	Feb	Mar	Apr	May	
Discovery Administrative Overhead	69	68	69	69	68	69	69	68	69	69	68	69	674	824	674	2,756	18	
Discovery Functional	240	243	259	255	210	233	215	208	209	219	221	226	2,738	3,061	4,099	(1,038)		
Discovery Ser/Prt/Sold-Internal	265	299	442	446	429	502	390	473	252	151	233	217	1,631	1,631	1,631	(163)		
Discovery Services Sold-External	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	(57)	
Total Discovery (less overhead)	505	542	701	701	639	735	605	681	461	370	454	413	6,837	5,817	5,817	(1,020)		
Drug Safety																		
Metabolism	17	18	25	29	32	63	55	39	21	26	25	21	371	416	416	45		
Toxicology/Pathology	22	25	28	26	16	43	28	19	37	9	10	63	326	163	163	(163)		
Comparative Medicine	34	60	129	121	41	100	25	34	7	14	20	26	611	554	554	(57)		
Strategic and Exploratory	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	
Medical Affairs																		
Outcomes Res/Admin																		
Medical Services																		
Phase-IIV																		
Phase-I Center																		
Clinical																		
ACRPU - Direct																		
Development Operations																		
Data Management																		
BioStatistics																		
Research Information Circ																		
Information Mgmt & Tech																		
International Manpower																		
Grants - Domestic																		
R&D Project Services																		
International Directors																		
Venture Management																		
PARD																		
Regulatory Affairs																		
Research QA																		
Investigational Drug QA																		
SPD																		
Genstar Credit																		
Other Judgment																		
Total	649	716	913	970	843	1,059	815	841	617	515	592	648	9,218	7,819	7,819	(1,319)		
COMMENTS																		

CONFIDENTIAL  
ABBTO578006

PHARMACEUTICAL PRODUCTS R&D  
GLOBAL DELIVERY PROJECT EXPENSE REPORT  
QUINOLONE ABT-492

	Jan	Feb	March	April	MONTHLY RESULTS						YTD Total	Approved APU	Var	
					Max	June	July	Aug	Sep	Oct				
Discovery	220	327	355	488	246	229	88	251	86	287	186	88	2,851	2,829
Drug Safety														(22)
Metabolism	55	114	194	111	127	142	110	112	84	61	71	75	1,256	910
Toxicology/Pathology	28	53	50	61	134	108	57	40	26	24	28	29	1,375	1,316
Comparative Medicine	1	38	36	23	39	29	22	19	23	28	26	26	310	737
Strategic and Exploratory														(193)
Medical Affairs														
Outcomes Res/Admin														
Medical Services	4	3	4	4	4	4	3	4	3	4	4	4	45	41
Phase-IV														(4)
Phase-I Center														
Clinical	3	4	6	12	19	15	19	15	19	12	14	9	10	155
ACPRU - Direct														
Development Operations	14	38	25	38	20	15	10	21	14	18	22	17	252	374
Data Management	11	10	39	22	29	35	16	26	19	13	19	13	252	309
Biostatistics	1	6	10	2	3	(22)	"	"	"	"	"	"	"	57
Research Information Ctr														
Information Mgmt & Tech														
International Manpower	71	41	52	75	96	77	248	110	110	(358)	"	"	"	122
Grants - Domestic	170	(40)	152	152	290	464	464	735	572	603	"	"	"	412
R&D Project Services														(1)
International Directors	8	8	11	5	3	9	5	10	5	(51)	(51)	(14)	4,197	5,000
Venture Management	124	118	132	214	(58)	107	124	70	97	100	120	74	179	(179)
PARD	115	179	185	203	207	271	202	169	241	225	597	114	1,222	53
Regulatory Affairs	5	6	3	5	9	46	5	27	17	24	16	11	174	(11)
Research QA	6	"	9	2	17	22	1	14	11	8	6	6	114	122
Re-org														208
Investigational Drug QA	3	1	2	2	4	6	2	17	15	5	9	7	66	152
SPD	280	280	297	295	366	371	716	476	521	606	377	456	5,041	5,978
License Pymt/Royalty														937
Other														(400)
Judgment														83
Total	1,119	1,192	1,563	1,715	1,761	2,093	1,842	1,669	5,486	5,658	1,524	1,923	23,059	22,697

COMMENTS:

A) Unfavorable PARD variance due to effort on Impurity and color issues, as well as an apparent underestimate of the required effort in the April Update.

CONFIDENTIAL  
ABBOTT 0578007

**PHARMACEUTICAL PRODUCTS R&D**  
**GLOBAL DELIVERY PROJECT EXPENSE REPORT**  
**TSP PEPTIDE ABT310**

	Jan	Feb	March	April	May	June	MONTHLY RESULTS			Qtr	Year
							Act	Var	YTD		
Discovery	71	140	252	161	70	98	71	83	63	61	101
Drug Safety											
Metabolism	24	43	46	8	39	45	25	8	21	31	43
Toxicology/Pathology	2	10	2	6	14	20	(21)	2	2	6	1
Comparative Medicine	..	1	5	1	3	9	2	3	15	..	1
Strategic and Exploratory	..	..	..	..	..	..	..	..	..	..	..
Medical Affairs	..	..	..	..	..	..	..	..	..	..	..
Outcomes Res/Admin	1	1	1	1	1	1	1	1	1	1	1
Medical Services											
Phase-IV											
Phase-I Center											
Clinical	10	14	28	20	29	30	19	..	29	13	9
ACPRU - Direct											
Development Operations											
Data Management	7	6	6	9	3	14	11	13	8	10	9
Biostatistics	2	7	5	19	21	12	7	6	11	18	1
Research Information Ctr	..	1	1	5	11	(18)	..	..	..	..	..
Information Mgmt & Tech											
International Manpower											
Grants - Domestic	115	116	49	78	77	110	111	111	111	44	111
R&D Project Services	..	1	2	..	..	3	2	1	..	..	..
International Directors	1	1	1	..	2	..	..	3	3	2	2
Venture Management	61	58	56	108	25	36	20	140	63	72	58
PARD	55	158	133	136	98	204	94	114	73	118	117
Regulatory Affairs	1	3	..	6	4	25	5	3	3	10	3
Research QA	9	3	14	6	13	4	5	6	1	5	2
Re-org											
Investigational Drug QA	2	2	1	3	3	3	4	12	..	1	4
SPD	187	185	203	205	259	253	307	300	391	258	247
License Pymt/Royalty	..	..	1	..	..	..	..	..	..	..	..
Other											
Judgment											
Total	548	751	805	771	672	816	661	795	807	719	643
COMMENTS											

A) Increase due to higher manufacturing costs at Cooit.  
B) Delay in ROSS submissions and 5 month extension of end date for MOJ-302.

CONFIDENTIAL  
ABBTO578008

**PHARMACEUTICAL PRODUCTS R&D**  
**GLOBAL DELIVERY PROJECT EXPENSE REPORT**  
**MMPI DEVELOPMENT ABT770/ABTS18**

	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	MONTHLY RESULTS		YTD Total	Approved AEU	Var
													Discovery	Drug Safety			
Metabolism	22	77	107	151	76	163	10	13	16	10	3	"	"	648	948	300	
Toxicology/Pathology	77	95	99	50	47	34	45	6	4	5	15	21	498	480	(18)		
Comparative Medicine	117	164	122	139	83	23	(5)	(2)	1	5	12	2	661	713	52		
Strategic and Exploratory	28	29	21	15	4	"	"	"	"	"	"	"	97	111	14		
Medical Affairs	17	24	12	21	1	(75)	"	"	"	"	"	"	"	"	"	"	
Outcomes Res/Admin	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	
Medical Services	"	"	"	"	50	(50)	"	"	"	"	"	"	"	"	"	"	
Phase-IV	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	
Phase-I Center	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	
Clinical	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	
ACPRU - Direct	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	
Development Operations	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	
Data Management	4	4	9	12	11	8	2	4	1	2	1	1	1	61	56	(5)	
Biostatistics	1	1	2	8	2	4	8	1	2	1	1	1	1	29	47	18	
Research Information Ctr	2	3	3	3	3	(1)	"	"	"	"	"	"	"	"	"	"	
Information Mgmt & Tech	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	
International Manpower	16	1	2	2	2	2	6	1	6	1	(7)	"	"	23	23	"	
Grants - Domestic	64	64	64	64	64	64	64	64	64	(28)	"	"	"	200	200	"	
R&D Project Services	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	
International Directors	"	2	4	3	2	1	5	"	2	3	2	1	25	27	2		
Venture Management	70	66	65	123	27	42	23	160	72	82	66	106	902	805	(97)		
PARD	42	54	75	30	40	41	22	18	19	2	2	4	349	349	0		
Regulatory Affairs	5	6	6	2	1	12	1	2	2	3	2	2	2	44	72	28	
Research QA	13	3	15	8	10	5	"	4	5	9	5	2	79	70	(9)		
Re-org	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	
Investigational Drug QA	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	
SPD	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	
License Fynd/Royalty	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	
Other Judgment	"	"	"	"	"	"	"	"	"	"	"	"	"	363	363	"	
Total	481	603	621	682	326	321	176	(39)	120	153	111	142	3,697	4,414	717		

COMMENTS

Program Discontinued

CONFIDENTIAL  
ABBTO578009

**PHARMACEUTICAL PRODUCTS R&D**  
**GLOBAL DELIVERY PROJECT EXPENSE REPORT**  
**CCM ABT594**

	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	MONTHLY RESULTS		YTD Total	Approved APU	Var.	
													Actual	Budget				
Discovery	5	10	5	11	4	4	6	22	1	1	1	1	6	7	72	71	(1)	
Drug Safety																		
Metabolism	21	47	65	68	41	31	14	13	1	6	11	2	320	549	229			
Toxicology/Pathology	87	128	159	96	(24)	63	11	31	15	26	22	4	615	694	49			
Comparative Medicine	2	...	...	...	...	1	1	...	...	...	...	...	...	...	...	30	26	
Strategic and Exploratory	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Medical Affairs	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Outcomes Res/Admin	1	1	1	1	1	1	1	1	1	2	2	2	2	10	9	(1)		
Medical Services	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Phase-IV	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Phase-I Center	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Clinical	16	13	24	18	21	48	12	...	17	4	...	1	184	349	165			
ACPRU - Direct	...	...	...	...	...	...	...	...	...	...	...	...	...	...	207	207		
Development Operations	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Data Management	19	30	56	24	7	3	4	3	2	11	5	11	3	8	272	129	(143)	
Biostatistics	25	31	43	37	51	36	11	11	5	11	5	11	11	8	149	243	94	
Research Information Ctr	2	3	7	1	5	(18)	...	...	...	...	...	...	...	...	...	124	124	
Information Mgmt & Tech	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
International Manpower	4	...	...	...	1	1	1	1	1	1	1	1	1	1	5	9	4	
Grants - Domestic	100	111	111	111	111	111	111	111	111	111	111	111	111	111	100	100	...	
R&D Project Services	...	1	1	1	1	1	1	1	1	1	1	1	1	1	...	39	39	
International Directors	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Venture Management	655	339	357	911	(565)	329	320	381	340	303	304	494	4,168	3,655	(513)			
P&R/D	169	193	213	151	146	204	78	88	51	32	10	21	1,356	1,048	(306)			
Regulatory Affairs	1	1	2	2	4	35	10	4	3	4	2	6	74	132	58			
Research QA	14	19	16	10	19	12	6	19	5	3	4	2	129	81	(48)			
Re-org	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Investigational Drug QA	2	...	1	1	1	1	1	1	1	1	1	1	1	1	4	75	71	
SPD	...	...	28	47	31	36	127	36	31	(70)	31	31	31	328	357	29		
License Pymt/Royalty	...	...	1	1	1	1	1	1	1	1	1	1	1	1	1	141	140	
Other	...	...	1	1	1	1	1	1	1	1	1	1	1	1	1	134	134	
Judgment	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Total	1,123	817	988	1,377	(259)	788	603	609	491	310	393	581	7,821	8,210	389			

**COMMENTS**

A) Unfavorable variance due to milestone budgeting. The Plan is for 6 months of work, while the system projects it over 12 months. Venture is currently reviewing the Phase II results to determine what further funding may be required. Currently, the venture is at a "go/no-go" decision. If a "no-go" decision is granted, the venture has identified approx. \$1.5MM in expenses that would not be incurred. If a "go" decision is granted, approx. \$3MM would be required to fund the project for the rest of the year.

CONFIDENTIAL  
ABBT0578010

**PHARMACEUTICAL PRODUCTS R&D**  
**GLOBAL DELIVERY PROJECT EXPENSE REPORT**  
**ENDOTHELIN ABT627**

	MONTHLY RESULTS												YTD			
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	YTD Total	Approved A/R	Var.	
Discovery	7	13	23	9	14	3	2	4	32	49	41	26	223	160	(63)	
Drug Safety																
Metabolism	31	51	24	37	46	19	47	56	21	18	27	43	420	991	571	
Toxicology/Pathology	"	3	"	"	3	4	3	"	"	5	"	3	21	349	328	23
Comparative Medicine	3	"	"	"	"	"	"	"	"	"	"	"	3	26	"	"
Strategic and Exploratory	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"
Medical Affairs	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"
Outcomes Res/Admin	11	35	30	26	38	6	22	25	28	14	16	53	304	259	(45)	
Medical Services	16	17	16	16	16	16	17	16	16	16	17	178	195	178	(17)	
Phase-IV	"	"	"	"	"	"	"	"	"	"	"	"	183	183	"	(183)
Phase-I Center																
Clinical	20	32	27	12	30	47	30	(14)	56	62	(14)	12	300	579	279	
ACPRU - Direct	"	"	"	"	"	"	"	"	"	"	"	6	6	6	6	690
Development Operations																
Data Management	56	51	68	48	55	37	34	33	31	53	28	51	545	1,596	1,051	
BioStatistics	79	92	80	109	67	68	60	74	56	55	62	64	866	743	(123)	
Research Information Ctr	5	7	11	4	5	(32)	"	"	"	"	"	"	"	"	"	"
Information Mgmt & Tech	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"
International Manpower	22	12	15	15	15	17	3	3	3	(6)	"	"	98	170	72	
Grants - Domestic	1,035	1,035	1,035	776	1,018	1,033	1,944	1,913	1,943	1,719	2,055	17,371	18,044	673		
R&D Project Services	13	7	9	12	"	10	7	3	4	5	2	(72)	"	22	22	
International Directors	10	11	32	28	29	23	23	42	25	28	22	11	284	154	(130)	
Venture Management	548	506	504	950	216	1,413	712	(249)	571	648	459	713	6,991	6,596	(395)	
PARD	217	342	429	253	538	553	311	413	378	365	385	955	5,139	3,562	(1,577)	
Regulatory Affairs	17	13	13	25	16	49	14	22	14	24	21	18	246	415	169	
Research QA	31	14	15	29	27	12	44	8	11	5	27	4	227	428	201	
Re-org	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"
Investigational Drug QA	15	11	24	14	22	16	19	16	9	19	13	18	196	262	66	
SPD	41	41	41	40	(146)	41	41	40	226	41	43	40	489	653	194	
License Pymt/Royalty	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	
Other	"	"	"	"	"	"	"	"	"	"	"	"	(40)	(40)	"	
Judgment	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	
Total	2,177	2,293	2,396	2,664	1,767	3,320	2,432	3,415	3,350	2,873	4,994	34,107	35,874	1,767	"	
COMMENTS																

- A) Increase in P&R due to last minute charges from Cook
- B) Accrual for PMO-724 delayed 1 month/debt in ROSS submittion M01-304, offset by accelerated spending
- C) M01-283 Qtr study on hold

CONFIDENTIAL  
ABBT0578011

**PHARMACEUTICAL PRODUCTS R&D**  
**GLOBAL DISCOVERY PROJECT EXPENSE REPORT**  
**ERECTILE DYSFUNCTION**

	MONTHLY RESULTS												YTD			Approved APU			Var
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	Total	YTD	APU	Var			
Discovery Administrative Overhead	65	65	65	65	65	64	64	65	65	65	65	65	65	779	779	"			
Discovery Functional	185	199	179	182	188	187	249	251	230	215	253	234	2,220	2,220	(342)				
Discovery Svc Purch/Sold-Internal	154	379	344	346	348	468	271	117	91	129	99	80	2,816	1,672	(1,174)				
Discovery Services Sold-External	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"		
Total Discovery (less overhead)	339	578	523	548	536	655	520	368	321	354	352	314	5,408	3,892	(1,516)				
Drug Safety																			
Metabolism	14	21	52	72	46	49	26	29	24	34	27	22	416	304	(112)				
Toxicology/Pathology	2	9	12	20	43	23	4	19	8	18	11	94	263	2	(261)				
Comparative Medicine	50	23	73	64	48	49	54	47	38	46	45	48	585	934	349				
Strategic and Exploratory	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"		
Medical Affairs																			
Outcomes Res/Admin																			
Medical Services																			
Phase-IV																			
Phase-I Center																			
Clinical																			
ACPRU - Direct																			
Development Operations																			
Data Management																			
Biostatistics																			
Research Information Ctr																			
Information Mgmt & Tech																			
International Manpower																			
Grants - Domestic																			
R&D Project Services																			
International Directors																			
Venture Management																			
PARD																			
Regulatory Affairs																			
Research QA																			
Investigational Drug QA																			
SPD																			
Genset Credit																			
Other																			
Judgment																			
Total	471	696	725	771	741	812	667	530	458	520	500	543	7,464	5,922	(1,542)				
COMMENTS																			

CONFIDENTIAL  
ABBT0578012

**PHARMACEUTICAL PRODUCTS R&D  
GLOBAL DELIVERY PROJECT EXPENSE REPORT  
DOPAMINE**

28-Jan-07  
PAGE B-4

	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	Total	YTD Approved	YTD Acru	YAC	MONTHLY RESULTS	
																	YTD	YAC
Discovery																		
Drug Safety																		
Metabolism																		
Toxicology/Pathology																		
Comparative Medicine																		
Strategic and Exploratory																		
Medical Affairs																		
Outcomes Res/Admin																		
Medical Services																		
Phase-IV																		
Phase-I Center																		
Clinical																		
ACPRU - Direct																		
Development Operations																		
Data Management																		
Biostatistics																		
Research Information Ctr																		
Information Mgmt & Tech																		
International Manpower																		
Grants - Domestic																		
R&D Project Services																		
International Directors																		
Venture Management																		
PARD																		
Regulatory Affairs																		
Research QA																		
Re-org																		
Investigational Drug QA																		
SPD																		
License Pymt/Royalty																		
Other																		
Judgment																		
Total																		
COMMENTS																		

CONFIDENTIAL  
ABBT0578013

**PHARMACEUTICAL PRODUCTS R&D**  
**GLOBAL DELIVERY PROJECT EXPENSE REPORT**  
**EISAI ABT-751**

	MONTHLY RESULTS												YTD Total	Approved AGL	YTD Var
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec			
Discovery	22	24	22	11	8	21	4	31	19	25	7	1	195	193	(2)
Drug Safety															
Metabolism	4	1	2	32	2	4	13	40	32	30	40	45	245	694	449
Toxicology/Pathology	2	6	24	57	17	23	18	8	17	6	5	1	184	202	18
Comparative Medicine	1	...	6	3	...	...	...	...	...	...	1	...	11	103	92
Strategic and Exploratory	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Medical Affairs	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Outcomes Res/Admin	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Medical Services	...	2	1	...	1	1	1	1	1	1	1	1	10	9	(1)
Phase-IV	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Phase-I Center	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Clinical	1	2	2	4	2	2	1	6	7	2	2	15	40	118	78
ACPRU - Direct	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Development Operations	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Data Management	...	...	1	2	2	1	1	4	10	8	5	8	11	52	73
Biostatistics	...	1	1	1	1	1	1	1	1	1	1	1	1	11	21
Research Information Ctr	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Information Mgmt & Tech	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
International Manpower	...	4	...	...	...	...	...	...	...	...	...	...	...	...	...
Grants - Domestic	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
R&D Project Services	...	2	2	3	...	2	2	1	...	1	1	1	1	549	945
International Directors	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Venture Management	200	190	187	353	80	121	66	461	208	234	188	305	2,593	2,577	(16)
PARD	139	191	242	127	85	93	52	117	110	136	139	152	1,583	1,231	(352)
Regulatory Affairs	...	...	1	4	3	2	3	2	3	1	2	3	...	...	...
Research QA	...	...	2	4	2	3	4	2	...	...	2	1	20	48	28
Re-org	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Investigational Drug QA	...	4	11	7	4	7	4	4	1	5	7	75	75	36	153
SPD	76	84	76	75	75	75	105	75	75	75	75	78	944	1,172	228
License Pymt/Royalty	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Other	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Judgment	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Total	450	507	579	683	281	353	274	479	765	...	...	...	6,503	7,681	1,178
COMMENTS	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....

A) Delay in ROSS submission (MO-231 &amp; MO-1303

CONFIDENTIAL  
ABBTO578014

PHARMACEUTICAL PRODUCTS R&D  
GLOBAL DELIVERY PROJECT EXPENSE REPORT  
KETOLIDE ABT773

	MONTHLY RESULTS												YTD Approved		YTD Total	YTD Approved	YTD Var.	
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	Jan	Feb				
Discovery	185	219	269	210	234	296	210	271	214	284	258	84	2,734	2,419	(315)			
Drug Safety																		
Metabolism	45	76	105	94	97	103	42	67	98	157	130	140	1,154	1,036	(118)			
Toxicology/Pathology	9	43	46	93	174	24	16	23	20	7	11	4	470	674	204			
Comparative Medicine	48	51	56	21	12	..	5	15	13	27	15	23	286	46	(240)			
Strategic and Exploratory	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	
Medical Affairs	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	
Outcomes Res/Admin	..	2	2	1	26	7	3	6	8	2	8	12	77	100	23			
Medical Services	70	69	70	69	70	70	69	69	70	70	69	69	835	696	(139)			
Phase-IV	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	
Phase-I Center	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	
Clinical	35	102	63	97	72	69	39	21	358	112	(192)	35	831	957	126			
ACPRU - Direct	155	264	108	-	-	-	-	-	258	-	190	260	102	1,337	1,040	(297)		
Development Operations																		
Data Management	51	92	154	159	208	206	162	207	123	167	191	154	1,874	3,033	1,159			
Biostatistics	65	66	89	93	103	94	78	87	89	74	106	75	1,019	1,252	233			
Research Information Ctr	33	35	51	57	30	(206)	..	..	..	..	..	..	..	..	..	..	..	
Information Mgmt & Tech	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	
International Manpower	172	151	146	200	230	159	279	129	167	..	(575)	..	1,058	979	(79)			
Grants - Domestic	5,541	5,432	5,606	5,608	5,605	200	(23)	162	2,401	2,414	7,710	46,197	47,031	834				
R&D Project Services	7	6	7	6	..	14	5	13	8	8	9	239	322	142	(180)			
International Directors	74	67	97	77	68	87	40	53	61	45	55	50	774	456	(318)			
Venture Management	619	588	661	1,072	(292)	537	620	348	483	500	598	375	6,109	5,310	(799)			
PARD	343	459	643	765	575	544	477	523	257	543	1,231	998	7,358	4,899	(2,459)			
Regulatory Affairs	4	18	15	8	13	262	41	58	35	20	43	29	546	450	(96)			
Research QA	28	23	76	63	36	89	63	85	40	20	28	30	581	446	(135)			
Re-org																		
Investigational Drug QA	17	33	26	28	17	17	6	12	6	14	20	15	211	417	206			
SPD	908	564	2,581	134	(1,912)	555	1,939	113	602	601	464	464	7,013	13,770	6,757			
License Pmt/Royalty	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..		
Other Judgment	..	..	2	..	..	..	..	..	..	..	..	..	315	4	(519)	2	533	
Total COMMENTS	8,429	8,471	10,697	8,853	5,369	8,532	4,295	2,335	2,813	5,557	5,148	10,289	80,788	85,136	4,348	====	====	

A) Unfavorable variance due to omission of a dog study in the April Update by Comparative Medicine.  
B) Decrease in Clinical Grant expense reflects increase in duration of Phase III studies.  
C) Favorable SPD variance reflects delay in receipt of bulk drug.

CONFIDENTIAL  
ABBTO578015

**PROOF OF SERVICE**

I, Marie A. Contreras, declare:


1. I am over the age of 18 and not a party to the within cause. I am employed by Munger, Tolles & Olson LLP in the County of Los Angeles, State of California. My business address is 355 South Grand Avenue, Suite 3500, Los Angeles, California 90071-1560.
2. On August 3, 2007, I served the original and/or a true and correct copy of the document entitled **ABBOTT LABORATORIES' AMENDED RESPONSES AND OBJECTIONS TO PLAINTIFFS' SECOND SET OF INTERROGATORIES** on the interested parties in this action by placing a true copy thereof enclosed in a sealed envelope, mailed as marked below, and addressed as follows:

*See Attached Service List*

- U.S. Mail:** I am "readily familiar" with the firm's practice of collection and processing correspondence for mailing. Under that practice it would be deposited with the U.S. postal service on that same day with postage thereon fully prepaid at Los Angeles, California in the ordinary course of business. I am aware that on motion of the party served, service is presumed invalid if postal cancellation date or postage meter date is more than one day after date of deposit for mailing affidavit.
- Federal Express:** I am "readily familiar" with the firm's practice of collection and processing correspondence for delivery to an employee of Federal Express. Under that practice it would be delivered to an employee of Federal Express on that same day at Los Angeles, California with charges to be billed to Munger, Tolles & Olson LLP's account to be delivered to the offices of the addressee(s) on \_\_\_\_\_ in the ordinary course of business.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on August 3, 2007, at Los Angeles, California.



Marie A. Contreras

**SERVICE LIST**

Hancock, et al. v. Abbott Laboratories  
Case No. 05-11150-DPW

Joseph H. Zwicker  
Choate, Hall & Stewart LLP  
Two International Place  
Boston, MA 02110  
Telephone:(617) 248-5076  
Facsimile: (617) 248-4000  
Email: jzwicker@choate.com

Michael S. D'Orsi  
Donnelly, Conroy & Gelhaar, LLP  
1 Beacon Street  
33rd Floor  
Boston, MA 02108  
Telephone:(617) 720-2880  
Facsimile: (617) 720-3554  
Email: msd@dcglaw.com



**PHARMACEUTICAL PRODUCTS R&D**  
**GLOBAL DISCOVERY PROJECT EXPENSE REPORT**  
**FARNESYLTRANSFERASE**

	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	YTD Total		YTD Approved APU		Var.
													Des	YTD Total	Des	YTD Total	
Discovery Administrative Overhead	69	68	69	69	68	69	69	68	69	69	68	69	69	824	824	824	"
Discovery Functional	240	243	259	255	210	233	215	208	209	219	221	226	219	2,738	2,756	18	
Discovery Svc Prcd/Sold-Internal	265	299	442	446	429	502	390	473	252	151	233	217	217	4,099	3,061	(1,038)	
Discovery Service Sold-External	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	"
Total Discovery (less overhead)	505	542	701	701	639	735	605	681	461	370	454	443	443	6,837	5,817	(1,020)	
Drug Safety																	
Metabolism	17	18	25	29	32	63	55	39	21	26	25	21	21	371	416	45	
Toxicology/Pathology	22	25	28	26	16	43	28	19	37	9	10	63	63	326	163	(163)	
Comparative Medicine	34	60	129	121	41	100	25	34	7	14	20	26	26	611	554	(57)	
Strategic and Exploratory	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	"
Medical Affairs																	
Outcomes Res/Adm/																	
Medical Services																	
Phase-IV																	
Phase-I Center																	
Clinical																	
ACPRU - Direct																	
Development Operations																	
Data Management																	
Biostatistics																	
Research Information Ctr																	
Information Mgmt & Tech																	
International Manpower																	
Grants - Domestic																	
R&D Project Services																	
International Directors																	
Venture Management																	
PARD																	
Regulatory Affairs																	
Research QA																	
Investigational Drug QA																	
SPD																	
Genser Credit																	
Other																	
Judgment																	
Total	649	716	953	970	843	1,059	815	617	515	592	648	9,218	7,819	(1,399)	====	====	

COMMENTS

CONFIDENTIAL  
ABBTO578006

**PHARMACEUTICAL PRODUCTS R&D**  
**GLOBAL DELIVERY PROJECT EXPENSE REPORT**  
**QUINOLONE ABT492**

	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	MONTHLY RESULTS			YTD Total	YTD Approved APU	Var	
													200	327	355	488	246	229	88
Discovery	220	327	355	488	246	229	88	251	86	287	186	88	2,851	2,829	(12)				
Drug Safety	55	114	194	111	127	142	110	112	84	61	71	75	1,256	910	(446)				
Metabolism	28	53	50	61	134	108	57	40	26	24	28	29	638	1,375	737				
Toxicology/Pathology	1	38	36	23	39	29	22	19	23	28	26	26	310	117	(193)				
Comparative Medicine																			
Strategic and Exploratory																			
Medical Affairs																			
Outcomes Res/Admin																			
Medical Services	4	3	4	4	4	4	3	4	3	4	4	4	45	41	(4)				
Phase-IV																			
Phase-I Center	3	4	6	12	19	15	19	15	19	12	12	12	88	..		10	155	279	124
Clinical																	100	83	(17)
ACPRU - Direct																			
Development Operations	14	38	25	38	20	15	10	21	14	18	22	17	252	374	122				
Data Management	11	10	39	22	29	35	16	26	19	13	19	13	252	309	57				
Biostatistics																			
Research Information Ctr	1	6	10	2	3	(22)	..	..	..	..	..	..							
Information Mgmt & Tech																	412	409	(1)
International Manpower	71	41	52	75	96	77	248	110	110	110	110	110	572	603	5,000	803			
Grants - Domestic	170	(40)	152	152	152	290	464	464	463	755	755	755	179						(179)
R&D Project Services																	64	53	(11)
International Directors	8	8	11	5	3	9	5	10	5	10	5	10	74	1,222	1,123	(9)			
Venture Management	124	118	132	214	(58)	107	124	70	97	100	120	120	114	2,728	951	(1,777)			
PARD	115	179	185	203	207	271	207	189	241	225	225	225	174	174	100	(74)			
Regulatory Affairs	5	6	3	5	9	46	5	27	17	24	16	16	11	11	114	322	208		
Research QA	6	..	9	2	17	22	1	14	11	8	6	6							
Re-org																			
Investigational Drug QA	3	1	2	2	4	6	2	17	15	5	9	9	456	66	152	86			
SPD	280	280	297	295	366	371	716	476	521	606	377	377	5,041	5,978	937				
License Pymt/Royalty													3,000	3,000	2,600	(400)			
Other																83	83	8	
Judgment																3	(192)	(193)	
Total	1,119	1,192	1,563	1,715	1,417	1,761	2,093	1,862	1,669	5,486	1,658	1,524	23,059	22,897	(167)				

COMMENTS:  
 A) Unfavorable PARD variance due to effort on impurity and color issues, as well as an apparent underestimate of the required effort in the April Update.

CONFIDENTIAL  
 ABBT0578007

**PHARMACEUTICAL PRODUCTS R&D**  
**GLOBAL DELIVERY PROJECT EXPENSE REPORT**  
**TSP PEPTIDE ABT510**

	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	MONTHLY RESULTS		YTD Total	YTD Approved A&U	YR YTD	
													Jan	Feb	Mar	Apr	May	
Discovery	71	140	252	161	70	98	71	83	63	61	101	76	1,247	1,704	457			
Drug Safety	24	43	46	8	39	45	25	8	21	31	43	33	366	1,045	679			
Metabolism	2	10	2	6	14	20	(21)	2	2	6	1	1	45	164	119			
Toxicology/Pathology	1	5	1	3	9	2	3	15	15	15	1	1	41		(41)			
Comparative Medicine																		
Strategic and Exploratory																		
Medical Affairs																		
Outcomes Res/Admin																		
Medical Services																		
Phase-IV																		
Phase I Center																		
Clinical	10	14	28	20	29	30	19	29	13	9	8	209	205		(4)			
ACPRU - Direct																		
Development Operations																		
Data Management	7	6	6	9	3	14	11	13	8	10	9	5	101	88	(13)			
Biostatistics	2	7	5	19	21	12	7	6	11	18	1	6	115	120	5			
Research Information Ctr		1	1	5	11	(18)												
Information Mgmt & Tech																		
International Manpower																		
Grants - Domestic	115	116	49	78	77	110	111	111	44	111	111	111	1,110	1,444	334			
R&D Project Services																		
International Directors	1	1	1	1	2	1	2	1	2	3	3	2	15	29	14			
Venture Management	61	58	56	108	25	36	20	40	63	72	58	92	789	756	(33)			
PARD	55	158	133	136	98	204	94	114	73	118	117	94	1,394	1,139	(255)			
Regulatory Affairs	1	3	14	6	13	4	5	3	10	3	1	5	64	74	10			
Research QA	9	3	14	6	13	4	5	6	1	5	5	2	73	56	(17)			
Re-org																		
Investigational Drug QA																		
SPD	187	185	203	205	259	253	307	300	391	258	247	369	3,164	3,383	219			
License Pym/Royalty																		
Other																		
Judgment																		
Total	548	751	805	771	672	816	661	795	807	719	643	806	8,794	10,275	1,481			

**COMMENTS**

A) Increase due to higher manufacturing costs at Cook.  
B) Delay in ROSS submissions and 5 month extension of end date for M01-302.

**CONFIDENTIAL**  
**ABBTO578008**

**PHARMACEUTICAL PRODUCTS R&D**  
**GLOBAL DELIVERY PROJECT EXPENSE REPORT**  
**MMP1 DEVELOPMENT ABT776/ABT518**

	Jan	Feb	March	April	MONTHLY RESULTS						Sept	Oct	Nov	Dec	YTD Total	YTD Approved AEU	Var.
					Jan	Feb	Mar	Apr	May	June							
Discovery	22	77	107	151	76	163	10	13	16	10	3	..	..	..	648	948	300
Drug Safety	77	95	99	50	47	34	45	6	4	5	15	21	498	480	(18)	..	..
Metabolism	117	164	122	139	83	23	(5)	(2)	1	5	12	2	661	713	52	..	..
Toxicology/Pathology	28	29	21	15	4	..	..	..	..	..	..	..	97	111	14	..	..
Comparative Medicine	17	24	12	21	1	(75)	..	..	..	..	..	..	..	..	..	..	..
Strategic and Exploratory	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Medical Affairs	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Outcomes Res/Admin	1	1	1	1	50	(50)	..	..	..	..	..	..	..	..	10	9	(1)
Medical Services	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Phase-IV	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Phase-I Center	1	3	5	3	3	1	1	1	1	1	1	1	1	1	23	119	96
Clinical	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
ACPRU - Direct	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Development Operations	4	4	9	12	11	8	2	4	1	3	2	1	61	56	(5)	..	..
Data Management	1	2	8	2	4	8	1	2	1	1	1	1	29	47	18	..	..
Biostatistics	2	3	3	3	..	..	..	..	..	..	..	..	..	..	..	..	..
Research Information Ctr	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Information Mgmt & Tech	16	1	2	2	2	2	6	1	7	7	..	..	..	..	23	23	..
International Manpower	64	64	64	64	64	64	64	64	(248)	..	..	..	..	..	200	200	..
Grants - Domestic	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
R&D Project Services	..	..	..	..	..	..	..	..	..	..	..	..	..	..	25	27	1
International Directors	70	66	65	123	27	42	23	160	72	82	66	106	902	805	(97)	..	..
Venture Management	42	54	75	30	40	41	22	18	19	2	2	4	349	349	0	..	..
PARD	5	6	6	2	1	12	1	2	2	3	2	2	44	72	28	..	..
Regulatory Affairs	13	3	15	8	10	5	..	..	..	..	..	..	..	..	79	70	(9)
Research QA	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Re-org	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Investigational Drug QA	1	5	3	4	..	..	..	..	..	..	..	..	..	..	19	23	4
SPD	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	(29)
License Pymt/Royalty	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Other	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Judgment	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..
Total	481	603	621	682	326	321	176	(39)	120	153	111	142	3,697	4,414	717	..	..

COMMENTS

Program Discontinued

CONFIDENTIAL  
ABBOTT578009

PHARMACEUTICAL PRODUCTS R&D  
GLOBAL DELIVERY PROJECT EXPENSE REPORT  
CCM ABT994

	Jan	Feb	March	April	MONTHLY RESULTS						Dec	YTD Total	YTD Approved APJ	YTD Var	
					June	July	Aug	Sept	Oct	Nov					
Discovery	5	10	5	11	4	4	8	22	1	1	"	"	72	71	(1)
Drug Safety	21	47	65	68	41	31	14	13	1	6	11	2	320	549	229
Metabolism	87	128	159	96	(24)	63	11	31	31	15	26	22	655	694	49
Toxicology/Pathology	2	"	"	"	"	1	1	"	"	"	"	"	4	30	26
Comparative Medicine	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"
Strategic and Exploratory	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"
Medical Affairs	"	"	"	"	"	"	"	"	"	"	"	"	"	34	34
Outcomes Res/Admin	1	1	1	"	"	1	1	"	2	"	"	2	10	9	(1)
Medical Services	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"
Phase-IV	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"
Phase-I Center	16	13	34	18	21	48	12	"	17	4	"	1	184	349	165
Clinical	"	"	"	"	"	"	"	"	"	"	"	"	"	207	207
ACPRU - Direct	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"
Development Operations	19	30	56	24	7	3	4	3	2	"	"	1	149	243	94
Data Management	25	31	43	37	51	36	11	11	5	11	3	8	272	129	(143)
Biostatistics	2	3	7	1	5	(18)	"	"	"	"	"	"	"	124	124
Research Information Ctr	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"
Information Mgmt & Tech	"	"	"	"	"	"	"	"	"	"	"	"	5	9	4
International Manpower	4	"	"	"	"	"	"	"	"	"	"	"	100	100	"
Grants - Domestic	100	"	"	"	"	"	"	"	"	"	"	1	(8)	"	39
R&D Project Services	"	1	1	"	"	3	"	"	2	"	"	"	"	"	"
International Directors	"	"	"	"	"	"	"	"	"	"	"	"	"	3,655	(513)
Venture Management	655	339	357	911	(565)	329	320	381	340	303	304	494	4,168	3,356	1,048
PARD	169	193	213	151	146	204	78	88	51	32	10	21	1,356	1,048	(308)
Regulatory Affairs	1	1	2	2	4	35	10	4	3	4	3	2	74	132	58
Research QA	14	19	16	10	19	12	6	19	5	3	4	2	129	81	(48)
Re-org	2	"	1	"	"	"	"	"	1	"	"	(1)	4	75	71
Investigational Drug QA	"	"	28	47	31	36	127	36	31	(70)	31	31	328	357	29
SPD	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"
License Pymt/Royalty	"	"	"	"	"	"	"	"	"	"	"	1	141	140	"
Other	"	"	"	"	"	"	"	"	"	"	"	"	134	134	"
Judgment	"	"	"	"	"	"	"	"	"	"	"	"	"	"	"
Total	1,123	817	988	1,377	(259)	788	603	609	491	310	393	581	7,821	8,210	389

COMMENTS

A) Unfavorable variance due to milestone budgeting. The Plan is for 6 months of work, while the system projects it over 12 months. Venture is currently reviewing the Phase II results to determine what further funding may be required. Currently, the venture is at a "go" / "no-go" decision. If a "go" decision is granted, the venture has identified approx. \$1.5MM in expenses that would not be incurred. If a "no-go" decision is granted, approx. \$9MM would be required to fund the project for the rest of the year.

CONFIDENTIAL  
ABBTO578010

**PHARMACEUTICAL PRODUCTS R&D**  
**GLOBAL DELIVERY PROJECT EXPENSE REPORT**  
**ENDOTHELIN ABT627**

	MONTHLY RESULTS												YTD			
	Jan	Feb	March	April	May	June	July	Aug	Sep	Oct	Nov	Dec	Total	Approved APU	Var	
Discovery	7	13	23	9	14	3	2	4	32	49	41	26	223	160	(63)	
Drug Safety																
Metabolism	31	51	24	37	46	19	47	56	21	18	27	43	420	991	571	
Toxicology/Pathology		3	...	...	3	4	3	...	...	5	3	3	21	349	318	
Comparative Medicine	3	...	...	...	...	...	...	...	...	...	...	...	3	26	73	
Strategic and Exploratory	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Medical Affairs	11	35	30	26	38	6	22	25	28	14	16	53	304	259	(45)	
Outcomes Res/Admin	16	17	16	16	16	17	16	16	16	16	17	17	195	178	(17)	
Medical Services	...	...	...	...	...	...	...	...	...	...	...	...	183	183	(18)	
Phase-IV	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Phase-I Center	20	32	27	12	30	47	30	(14)	56	62	(14)	12	300	579	279	
Clinical	...	...	...	...	...	...	...	...	...	...	6	...	6	6	690	
ACPRU - Direct	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Development Operations	56	51	68	48	55	37	34	33	31	53	28	51	545	1,596	1,051	
Data Management	79	92	80	109	67	68	60	74	56	55	62	64	866	743	(123)	
Biostatistics	5	7	11	4	5	(32)	...	...	...	...	...	...	...	...	...	
Research Information Ctr	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Information Mgmt & Tech	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
International Manpower	22	12	15	17	15	17	3	3	(6)	...	...	...	...	98	170	72
Grants - Domestic	1,035	1,035	1,035	776	1,018	1,033	1,944	1,943	1,719	2,855	1,7371	18,044	673	22	22	
R&D Project Services	13	7	9	12	...	10	7	3	4	5	2	(72)	...	...	...	
International Directors	10	11	32	28	29	23	23	42	25	28	22	11	284	154	(130)	
Venture Management	548	506	950	216	1,413	712	(249)	571	648	459	713	6,991	6,996	(395)	(1,577)	
PARD	217	342	429	253	538	553	311	413	378	365	955	5,139	3,562	1,69	415	
Regulatory Affairs	17	13	13	25	16	49	14	22	14	24	21	18	246	415	169	
Research QA	31	14	15	29	27	12	44	8	11	5	27	4	227	428	201	
Re-org	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Investigational Drug QA	15	11	24	14	22	16	19	16	9	19	13	18	196	262	66	
SPD	41	41	40	(146)	41	41	40	226	41	43	40	489	194	683	194	
License Pymt/Royalty	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Other	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
Judgment	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
<b>COMMENTS</b>	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	
<b>Total</b>	2,177	2,293	2,396	2,664	1,767	3,320	2,422	3,415	3,350	2,873	4,994	34,107	35,874	1,767	...	

- A) Increase in PARD due to last minute charges from Cook.
- B) Accrual for M001-244 delayed 1 month/1 month delay in ROSS submission M01-304, offset by accelerated spending
- C) M01-283 Qtc study on hold

CONFIDENTIAL  
ABBT0578011

PHARMACEUTICAL PRODUCTS R&D  
GLOBAL DISCOVERY PROJECT EXPENSE REPORT  
ERECTILE DYSFUNCTION

	MONTHLY RESULTS												YTD - Approved			
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	YTD Total	APU	Yar	
Discovery Administrative Overhead	65	65	65	65	64	65	65	65	65	65	65	65	779	779	(342)	
Discovery Functional	185	199	179	182	188	187	249	251	230	253	234	253	2,562	2,220	(1,174)	
Discovery Svc Purch/Sold-Internal	154	379	344	366	348	468	271	117	91	129	99	80	2,816	1,872	.....	
Discovery Service Sold-External	339	578	523	548	536	655	520	368	321	354	352	314	5,408	3,892	(1,516)	
Total Discovery (less overhead)	50	23	73	64	48	49	54	47	38	46	45	48	416	304	(112)	
Drug Safety	14	21	52	72	46	49	26	29	24	34	27	22	263	2	(261)	
Metabolism	2	9	12	20	43	23	4	19	8	18	11	94	585	934	349	
Toxicology/Pathology	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Comparative Medicine	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Strategic and Exploratory	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Medical Affairs	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Outcomes Res/Admin	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Medical Services	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Phase-IV	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Phase-I Center	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Clinical	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
ACPRU - Direct	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Development Operations	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Data Management	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Biostatistics	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Research Information Ctr	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Information Mgmt & Tech	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
International Manpower	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Grants - Domestic	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
R&D Project Services	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
International Directors	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Venture Management	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
PARD	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Regulatory Affairs	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Research QA	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Investigational Drug QA	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
SPD	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
General Credit	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
Other Judgment	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	
<b>Total</b>	<b>471</b>	<b>696</b>	<b>725</b>	<b>771</b>	<b>741</b>	<b>842</b>	<b>667</b>	<b>530</b>	<b>458</b>	<b>520</b>	<b>500</b>	<b>543</b>	<b>7,464</b>	<b>5,922</b>	<b>(1,542)</b>	

COMMENTS

CONFIDENTIAL  
ABBTO578012

**PHARMACEUTICAL PRODUCTS R&D  
GLOBAL DELIVERY PROJECT EXPENSE REPORT  
DOPAMINE**

PAGE B-4

	MONTHLY RESULTS												Desc	YTD Total	YTD Approved API	YTD Vat
	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec				
Discovery									83	29	3	72	187			(187)
Drug Safety									8	35	78	121				(171)
Metabolism									3	5	22	30				(30)
Toxicology/Pathology									4	4	24	28				(28)
Comparative Medicine																
Strategic and Exploratory																
Medical Affairs																
Outcomes Res/Admin																
Medical Services																
Phase-IV																
Phase-I Center																
Clinical																
ACPRU - Direct																
Development Operations																
Data Management																
Biostatistics																
Research Information Ctr																
Information Mgmt & Tech																
International Manpower																
Grants - Domestic																
R&D Project Services																
International Directors																
Venture Management																
PARD																
Regulatory Affairs																
Research QA																
Re-org																
Investigational Drug QA																
SPD																
License Pymt/Royalty																
Other																
Judgment																
Total									106	118	143	261				(628)

COMMENTS

CONFIDENTIAL  
ABBT0578013

PHARMACEUTICAL PRODUCTS R&D  
GLOBAL DELIVERY PROJECT EXPENSE REPORT  
EISAI ABT-751

	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	MONTHLY RESULTS			YTD Total	YTD Approved APJ	YTD At
													22	24	22	11	8	(2)
Discovery																		
Drug Safety	4	1	2	32	2	4	13	40	32	30	40	45	245	694	449			
Metabolism	2	6	24	57	17	23	18	8	17	6	5	1	184	202	18			
Toxicology/Pathology																		
Comparative Medicine	1	6	3	...	...	...	...	...	...	...	1	...	11	103	97			
Strategic and Exploratory	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Medical Affairs	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Outcomes R&A/Admin	2	1	...	...	...	...	...	...	...	...	...	...	10	9	(1)			
Medical Services	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Phase-IV	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Phase-I Center	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Clinical	1	2	2	4	2	2	1	...	7	2	2	15	40	118	78			
ACPRU - Direct	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Development Operations	...	...	1	2	2	1	4	10	8	5	8	11	52	73	21			
Data Management	...	1	1	1	1	1	1	2	1	1	1	1	11	81	79			
Biostatistics	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Research Information Ctr	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Information Mgmt & Tech	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
International Manpower	4	4	4	4	4	4	4	4	4	4	4	4	4	4	8	4	4	4
Grants - Domestic	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
R&D Project Services	...	2	2	3	...	2	2	1	...	1	...	...	...	...	...	...	...	...
International Directors	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Venture Management	200	190	187	353	80	121	66	461	208	234	188	305	2,593	2,577	(16)			
PARD	139	191	242	127	85	93	52	117	110	136	139	152	1,583	1,231	(353)			
Regulatory Affairs	...	1	4	3	7	2	3	1	2	3	2	2	26	73	47			
Research QA	...	...	2	4	2	3	4	2	...	...	...	1	20	48	28			
Re-org	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Investigational Drug QA	...	4	11	7	4	...	...	4	1	5	...	...	36	153	117			
SPD	76	84	76	75	75	105	75	75	75	75	75	78	944	1,172	228			
License Pymt/Royalty	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Other	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Judgment	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
<b>COMMENTS</b>																		
<b>Total</b>	<b>450</b>	<b>507</b>	<b>579</b>	<b>683</b>	<b>281</b>	<b>353</b>	<b>274</b>	<b>755</b>	<b>479</b>	<b>634</b>	<b>583</b>	<b>925</b>	<b>6,503</b>	<b>7,681</b>	<b>1,178</b>			

A) Delay in ROSS submission M00-231 &amp; M01-303

CONFIDENTIAL  
ABBTO578014

**PHARMACEUTICAL PRODUCTS R&D**  
**GLOBAL DELIVERY PROJECT EXPENSE REPORT**  
**KETOLIDE ABT773**

	Jan	Feb	March	April	May	June	July	Aug	Sept	Oct	Nov	Dec	MONTHLY RESULTS			YTD Total	YTD Approved APL	YTD Var
													Actual	Budget	Variance			
Discovery	185	219	269	210	234	296	210	271	214	284	258	84	2,734	2,419	(315)			
Drug Safety	45	76	105	94	97	103	42	67	98	157	130	140	1,154	1,006	(148)			
Metabolism	9	43	46	93	174	24	16	23	20	7	11	4	470	674	204			
Toxicology/Pathology	48	51	56	21	12	...	5	15	13	27	15	23	286	46	(240)			
Comparative Medicine	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...			
Strategic and Exploratory	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...			
Medical Affairs	...	2	2	1	26	7	3	6	8	2	8	12	77	100	23			
Outcomes Res/Admin	...	69	70	69	70	70	69	69	70	70	69	69	835	696	(139)			
Medical Services	70	...	...	...	...	...	...	...	...	...	...	...	...	...	...			
Phase-IV	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...			
Phase-I Center	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...			
Clinical	55	102	63	97	72	69	39	21	358	112	(192)	35	831	957	126			
ACPRU - Direct	155	264	198	...	...	...	...	...	258	...	190	260	102	1,337	1,040	(297)		
Development Operations	51	92	154	159	208	206	162	207	123	167	191	154	1,874	3,033	1,159			
Data Management	65	66	89	93	103	94	78	87	89	74	106	75	1,919	1,252	233			
Biostatistics	33	35	51	57	30	(206)	...	...	...	...	...	...	...	...	...			
Research Information Ctr	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...			
Information Mgmt & Tech	172	151	146	200	230	159	279	129	167	...	(575)	...	1,058	979	(79)			
International Manpower	5,541	5,432	5,606	5,608	5,605	200	(23)	162	2,401	2,414	7,710	46,197	47,031	834				
Grants - Domestic	7	6	7	6	...	14	5	13	8	8	9	239	322	142	(180)			
R&D Project Services	74	67	97	77	68	87	40	53	61	45	55	50	774	456	(318)			
International Directors	619	588	661	1,072	(292)	537	620	348	483	500	598	375	6,109	5,310	(799)			
Venture Management	343	459	643	765	575	544	477	523	257	543	1,231	998	7,358	4,899	(2,459)			
PARD	4	18	15	8	13	262	41	58	35	20	43	29	546	450	(96)			
Regulatory Affairs	28	23	76	63	36	89	63	85	40	20	28	30	581	446	(135)			
Re-org	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...			
Investigational Drug QA	17	33	26	28	17	17	6	12	6	14	20	15	211	417	206			
SPD	908	564	2,581	134	(1,912)	555	1,939	113	602	601	464	464	7,013	13,770	6,757			
License Pymt/Royalty	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...			
Other	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...			
Judgment	...	2	...	...	...	...	...	...	...	...	...	...	315	4	(319)	2	(519)	(521)
Total COMMENTS	8,429	8,471	10,697	8,853	5,369	8,532	4,295	2,335	2,813	5,557	5,148	10,289	80,788	85,136	4,348			

A) Unfavorable variance due to omission of a dog study in the April Update by Comparative Medicine.  
B) Decrease in Clinical Grant expense reflects increase in duration of Phase III studies.  
C) Favorable SPD variance reflects delay in receipt of bulk drug.

CONFIDENTIAL  
ABBOTT578015

**CERTIFICATE OF SERVICE**

I hereby certify that this document(s) filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non registered participants on February 18, 2008.

Date: February 18, 2008.

---

/s/ Eric J. Lorenzini

Eric J. Lorenzini (*pro hac vice*)